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1. ABBREVIATIONS  
 
3′UTR: 3′ Untranslated Region  
5-hmC: 5-hydroxymethyl-cytosine  
6-OHDA: 6-hydroxydopamine 
AADAC: Arylacetamide deacetylase  
ACP1: Acid phosphatase 1, soluble  
ADAM1: ADAM metallopeptidase domain 1A (pseudogene)  
ADHD: Attention Deficit Hyperactivity Disorder 
ADORA1: Adenosine A1 receptor  
ADORA2A: Adenosine A2a receptor  
AIM: Abnormal Involuntary Movement  
ARC: Activity regulated cytoskeleton associated protein  
ATF3: Activating transcription factor 3  
BAG3: BCL2 associated athanogene 3 
BLM: BLM RecQ like helicase  
Bp: Base Pair 
BRD1: Bromodomain containing 1 
BRPF3: Bromodomain and PHD finger containing 3  
BTBD9: BTB (POZ) domain containing 9 
CCND3: Cyclin D3  
CDC37: Cell division cycle 37  
CDH13: Cadherin 13 
CDH2: Cadherin 2, type 1, N-cadherin neuronal  
CDK19: Cyclin dependent kinase 19  
CDKN1A: Cyclin dependent kinase inhibitor 1A  
CHAT: Choline acetyltransferase  
CHRNA7: Cholinergic receptor, nicotinic, alpha 7 (neuronal)  
CLINT1: Clathrin interactor 1  
CNR1: Cannabinoid receptor 1  
CNTN6: Contactin-6  
CNTNAP2: Contactin associated protein-like 2   
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CNV: Copy Number Variation 
COL27A1: Collagen, type XXVII, alpha 1 
COL8A1: Collagen, type VIII, alpha 1  
COMMD1: COMM domain-containing protein 1  
COMT: Catechol-O-methyltransferase  
CpG: Cytosine-Phosphate-Guanine dinucleotide  
CREB1: cAMP-responsive element binding protein 1  
CREM: cAMP responsive element modulator  
CRH: Corticotropin releasing hormone  
CSRNP1: Cysteine and serine rich nuclear protein 1  
CSTC: Cortico-Striato-Thalamo-Cortical  
DA: Dopamine 
DMS: Differentially Methylated Site:  
DNMTs: DNA Methyltransferases  
DPP6: Dipeptidyl-peptidase 6  
DRD1: Dopamine receptor D1 
DRD2: Dopamine receptor D2  
DRD4: Dopamine receptor D4  
DSM-5: Diagnostic and Statistical Manual of Mental Disorders  
DUSP14: Dual specificity phosphatase 14  
EGR4: Early growth response 4  
EHD4: EH domain containing 4  
ESR: Early Stage Researcher  
EWAS: Epigenome-Wide Association Study  
FGF13: Fibroblast growth factor 13  
FOS: Fos proto-oncogene, AP-1 transcription factor subunit  
FOSB: FosB proto-oncogene, AP-1 transcription factor subunit  
FRMD6: FERM domain containing 6  
GAA: Glucosidase alpha, acid  
GABBR1: Gamma-aminobutyric acid type B receptor subunit 1  
GADD45B: Growth arrest and DNA damage inducible beta  
GADD45G: Growth arrest and DNA damage inducible gamma  
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GDNF: Glial cell Derived Neurotrophic Factor  
GGRI: GWAS Replication Initiative 
Gpe: Globus Pallidus Externus  
Gpi: Globus Pallidus Internus  
GPR3: G protein-coupled receptor 3  
GRIK3: Glutamate ionotropic receptor kainate type subunit 3 
GRIK4: Glutamate ionotropic receptor kainate type subunit 4 
GRIN2B: Glutamate ionotropic receptor NMDA type subunit 2B  
GRM4: Glutamate metabotropic receptor 4 
GRM8: Glutamate metabotropic receptor 8 
GSTP1: Glutathione s-transferase pi 1  
GWAS: Genome Wide Association Study  
HDC: Histidine decarboxylase  
hEAE6: Homolog of Esa1-associated factor 6  
HIST1H4E: Histone cluster 1 H4 family member e 
HPLC-ECD: Electrochemical detection technique coupled with high-performance liquid 
chromatography  
HSPA5: Heat shock protein family A (Hsp70) member 5  
HTR2A: 5-hydroxytryptamine Receptor 2A  
ID1: Inhibitor of DNA binding 1, HLH protein  
IGSF9B: Immunoglobulin superfamily member 9B  
Illumina 450K: Infinium HumanMethylation450 Bead Chip Kit  
ILR1N: Interleukin 1 receptor antagonist  
IMMP2L: Inner mitochondrial membrane peptidase subunit 2  
ING5: Inhibitor of growth 5  
INHBA: Inhibin beta A subunit  
IRS2: Insulin receptor substrate 2  
JUN: Jun proto-oncogene, AP-1 transcription factor subunit  
JUNB: JunB proto-oncogene, AP-1 transcription factor subunit  
KCNK9: Potassium channel two pore domain subfamily K member 9  
KLF4: Kruppel like factor 4 
LHX6: LIM homeobox 6  
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LMO1: LIM domain only 1  
MAOA: Monoamine oxidase A  
MCPerm: Monte Carlo Permutation  
MECP2: Methyl-CpG-binding protein 2 
MEIS1: Meis homeobox 1 
MIDN: Midnolin  
MORN4: MORN repeat containing 4 
NDUFV1: NADH ubiquinone oxidoreductase core subunit V1  
NFIL3: Nuclear factor, interleukin 3 regulated  
NPAS4: Neuronal PAS domain protein 4  
NPTX2: Neuronal pentraxin 2  
NPY: Neuropeptide Y  
NR4A1: Nuclear receptor subfamily 4 group A member 1  
NR4A3: Nuclear receptor subfamily 4 group A member 3  
NRGN: Neurogranin  
NRXN1: Neurexin 1  
NTN4: Netrin 4  
OCD: Obsessive-Compulsive Disorder 
OLFM1: Olfactomedin1  
OR: Odds Ratio  
Ov.T: Over-Transmitted  
P: P-value 
PANDAS: Pediatric Autoimmune Neuropsychiatric Disorder Associated with 
Streptococcal infection  
PARP1: Poly (ADP-ribose) polymerase 1  
PD: Parkinson’s disease 
PDE10A: Phosphodiesterase 10A  
PDXK: Pyridoxal kinase  
PDYN: Prodynorphin  
PER1: Period circadian clock 1  
PIGX: Phosphatidylinositol glycan anchor biosynthesis class X  
PIM3: Pim-3 proto-oncogene, serine/threonine kinase  
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PLAT: Plasminogen activator, tissue type  
PLEKHG3: Pleckstrin homology and RhoGEF domain containing G3  
PTGS2: Prostaglandin-endoperoxide synthase 2  
PVR: Poliovirus receptor 
RELN: Reelin RELN 
REM2: RRAD and GEM like GTPase 2  
RHEB: Ras homolog enriched in brain  
SCG2: Secretogranin II  
SEMA7A: Semaphorin 7A (John Milton Hagen blood group)  
SEMAG4G: Semaphorin-4G  
SERT: Serotonin transporter 
SERTAD1: SERTA domain containing 1  
SGK1: Serum/glucocorticoid regulated kinase 1  
SH3KBP1: SH3 domain containing kinase binding protein 1  
SIK1: Salt inducible kinase 1  
SLC25A48: SLC25A48 solute carrier family 25 member 48 
SLC32A1: Solute carrier family 32 member 1  
SLC6A3: Solute carrier family 6 member 3 
SLC6A4: Solute carrier family 6 (neurotransmitter transporter) member 4 
SLITRK1: SLIT and NTRK like family member 1 
SN: Substantia Nigra 
SNP: Single Nucleotide Polymorphism  
SNTG1: Syntrophin gamma 1  
SRXN1: Sulfiredoxin 1  
STAT3: Signal transducer and activator of transcription 3  
STN: Subthalamic Nucleus 
TAC1: Tachykinin precursor 1  
TDT: Transmission Disequilibrium Test 
TNF: Tumor necrosis factor  
TPH2: Tryptophan hydroxylase 2  
TS: Tourette Syndrome  
TSGeneSEE: The Tourette Syndrome Genetics - Southern and Eastern Europe Initiative  
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VEGFA: Vascular endothelial growth factor A  
VNTR: Variable Number of Tandem Repeat  
Vs: Versus  
WFS1: Wolframin ER transmembrane glycoprotein  
XRCC1: X-ray repair complementing defective repair 1 
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2.1 Tourette Syndrome 
 
Gilles de la Tourette Syndrome (TS) is a neurodevelopmental disorder characterized by 
the appearance of a vocal and multiple motor tics (DSM-5) [1]. To be diagnosed with TS, 
considered a rare disease affecting about 1% of the world population, the symptoms need 
to manifest for at least 1 year. It usually lasts only during childhood and adolescence and 
it affects most the boys than girls (4:1). The probability of transmitting the disorder to the 
next generation is  between 0.58 and 077 [2, 3] with a very high risk of inheritance in case 
of a first-degree relative (father-mother). To complicate the situation, TS rarely manifests 
alone: in 45-60% of the cases it goes along with obsessive-compulsive disorder (OCD) 
while in 60% of the cases it appears with attention deficit hyperactivity disorder (ADHD). 
OCD is one of the main disorders shared by TS patients. It is characterized by the presence 
of unwanted repetitive thoughts and behaviors [4]. Similar to Tourette, neuroimaging 
studies implicated the involvement of the cortico-striato-thalamo-cortical (CSTC) circuit 
in the pathophysiology (see below). Not surprisingly, genetic studies are pointing towards 
the involvement of serotonergic, glutamatergic and dopaminergic pathways, which are 
the same neurotransmitter implicated in TS (see below).  ADHD, the other principal 
disorder shared by TS patients, usually refers to different form of behavioral impairment 
that affect the quality of life of the children. The most common symptoms are the 
manifestation of hyperactivity, inattention, impulsivity and issues in establishing social 
interactions. The genetics of ADHD is extremely complex and as for TS there are not 
many significant findings at genome wide levels, although it is believed that the 
dopaminergic pathway is involved in the etiology of ADHD [5]. Other types of behavioral 
disorders, such as autism and learning disabilities are also usual comorbidities in 
individuals with TS. In order to gain more information on such a rare disease, usually less 
funded than the study of major diseases, the European Union established the Marie Curie 
Initial Training Network (TS-EUROTRAIN 2012-2016) [6]. This network was composed 
of 10 research centers spread across Europe employing 12 PhD students spread across 
Europe aiming to study TS from different angles (bioinformatics, animal model, genetic, 
DOI:10.14753/SE.2019.2338
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neuroimaging) and to combine all the new discoveries to have a clearer picture of the 
pathology (see below). 
 
2.1.1 TS Diagnosis 
 
DSM-5 provides the following guidelines that allow a person to be diagnosed with TS: 
 
 manifestation of at least two motor tics and at least one vocal tic  
 manifestation of tics for at least one year 
 manifestation of tics before the age of 18 
 manifestation of tics not related to the intake of any medicine/drug  
 manifestation of tics not related to other medical conditions 
 
2.1.2 Definition of tics 
 
A tic is usually defined as the appearance of an involuntary locomotor activity or vocal 
sound that manifests occasionally for a short amount of time with different frequency, 
intensity, duration or anatomical localization. As depicted in Table 1 a tic might be either 
vocal or motor, simple or complex [1]. 
 
Table 1: Classification of Tics 
 Motor Vocal 
Single blinking 
rolling the eye   
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In general, tics are more prone to manifest if the patient is in a situation of emotional 
distress, while they are reduced when the patient is focused/involved in daily activities 
[7]. The patient can usually feel when the tic is coming, a phenomenon called 
“premonitory urge”, and after the tic is released the patient experiences a sense of relief. 
The symptoms usually manifest during childhood and disappear at the end of adolescence 
following the typical waxing and waning pattern that characterizes Tourette Syndrome 
[8, 9]. In a few cases, the symptoms also persist into adulthood.  In some cases, the tics 
are subtle enough so that they do not affect too much the daily life of the patients, since 
they learnt very well how to control and live with them. However, in some cases, when 
tics are complex and severe, involving several body regions and loud vocalizations and 
the episodes last longer, they can be severely debilitating for the patients. 
 
2.1.3 The Cortico-Striato-Thalamo-Cortical Circuit 
 
The full neurobiological background of TS is not yet understood, but many scientific 
studies detected morphological and functional changes in the cortico-striato-thalamo-
cortical (CSTC) circuit [10-12]. The CSTC circuit (Fig. 1) is formed by the interaction 
between pre-motor and motor cortices, striatum, globus pallidus internus (GPi), globus 
pallidus externus (GPe), subthalamic nucleus (STN), thalamus, and substantia nigra (SN). 
The physiological activation of this circuit usually results in the manifestation of 
voluntary movements as well as the repression of involuntary movements. For a 
movement to manifest, the motor cortex needs to be activated by the thalamus, which is 
usually inhibited by the STN-GPe-GPi. The activation of the direct pathway starts after 
the release of glutamate leading to the activation of striatal projection to substantia niagra 
(SN) and globus pallidus interna (GPi). These GABAergic cells, which have an inhibitory 
action, block the SN. The inhibition of SN results in the activation of the thalamic 
glutamatergic neurons. The subsequent activation of the cortex leads to locomotor 
movements [13, 14]. An abnormal activity of the basal ganglia might lead to 
manifestation of tics as a consequence of the dysregulation of thalamic activity, as well 
as higher firing of the motor cortex [15, 16].  
DOI:10.14753/SE.2019.2338
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Fig. 1: Schematic diagram of the Cortico-Striato-Thalamo-Cortical (CSCT) circuit. 
The figure shows the area of the brain involved in the pathways that modulate both 
voluntary and involuntary movements. The green arrows indicate dopaminergic 
inputs, blue arrows indicate GABAergic inputs while the red arrows indicate 
glutamatergic inputs. 
 
2.1.4 The hidden heritability of TS 
 
Different studies analyzed the overall genetic contribution in the development of TS.  A 
meta-analysis performed using all the human twin studies established that the heritability 
of tics/tic disorders is 0.45 [17]. Two other genetic studies assessed that the heritability 
of TS and tic disorders is 0.58 and 0.77, respectively [2, 3] with an elevated risk for first-
degree relatives (father-mother). Heritability is a parameter that may help to understand 
the genetic architecture of complex disorders, and it usually refers to the proportion of 
the phenotypic abnormalities observed as a consequence of genetic variations [18]. The 
genetic variations identified in the association studies of Tourette Syndrome have been 
hinder by lack of statistical power, small sample sizes and clinical heterogeneity. It is 
DOI:10.14753/SE.2019.2338
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very unlikely that one single variation might cause all the variety of symptoms that appear 
in the patients. So, the genetic variations alone do not account for the overall TS 
heritability. Several other components might play a role. It is a phenomenon called 
“missed heritability” that might be explained by the contribution of environmental factors 
as well as epigenetic mechanisms in the development of TS (see below). 
 
2.2 Genetic background of Tourette Syndrome 
 
The following chapter describes some of the positive (but not always significant) genetic 
findings related to TS classified based on the extent of the DNA alteration: 
 
 copy number variations (CNVs) 
 variable number of tandem repeats (VNTRs) 
 single nucleotide polymorphisms (SNPs) 
 
Extensive literature research has been performed during this PhD project to identify 
potential candidate genes for genetic studies and it also resulted in the publication of a 
review on the genetic and epigenetic background of Tourette Syndrome [19]. It has been 
an exhaustive research, but it definitely does not include all the genetic studies ever 
published on TS. In the sections below, I am not going to described all the multiple and 
single positive studies involved in the literature research, because it is not the aim of this 
PhD thesis. I am going to provide a comprehensive genetic background that may help the 
reader to understand the reasoning behind the genetic and biological studies I performed 
during my PhD. More details about the genetic background of TS can be found in the 
published review [19]. 
 
2.2.1 CNVs and Tourette Syndrome  
 
CNVs are characterized by rearrangements of a relatively large genomic region in an 
individual. It usually involves a deletion or duplication of a chromosomal segment that 
may alter the biological function of genes contained within and lead to the development 
of a disease. 
DOI:10.14753/SE.2019.2338
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The most studied gene with regards to CNV and Tourette Syndrome is the inner 
mitochondrial membrane peptidase subunit 2 (IMMP2L). This gene, located on 
chromosome 7q31, encodes for a protein involved in handling the signal peptide 
sequences used to direct mitochondrial proteins to the mitochondria. It was first 
discovered in a large TS family that had a balanced translocation [20]. IMMP2L was later 
identified in a male patient that had a de novo duplication [21]. It was also found disrupted 
in a male patient with a breakpoint on 7q31.1 [22]. Most recently, a CNV study in a 
Danish cohort of 188 TS patients found intragenic deletion of IMMP2L in seven patients 
[23].  
In the last years many other CNVs have been associated to TS. One of the most robust 
study reported 8 patients with deletions of arylacetamide deacetylase (AADAC). This 
deletion was further investigated by meta-analysis in a large European sample of over 
1000 TS patients and 100,000 controls that confirmed the role of AADAC deletions in TS 
pathogenesis [24].  
The same lab  [25] also reported the case of a patient with TS, OCD and ADHD carrying 
a de novo translocation leading to a truncation of the olfactomedin1 (OLFM1) gene. 
OLFM1 is highly expressed in hippocampus and cerebral cortex and might have a role in 
a proper neuronal functioning [26]. 
One study focusing on large genomic rearrangements discovered a large duplication 
(600kb) of collagen type VIII alpha 1 chain (COL8A1) in 4 TS patients and a big deletion 
(400kb) of neurexin 1 (NRXN1) in 2 TS patients [27]. COL8A1 plays structural role and 
contribute to organization, shape and mechanical properties of tissues and it has been 
linked to neural development throughout axonal guidance and synaptogenesis [28], while 
NRXN1 mediates cell-cell interactions in the central nervous system and it has been 
associated to autism and schizophrenia  [29, 30]. The involvement of exonic NRXN1 
deletions with the development of TS has been previously reported a Danish TS cohort 
[31] and also been recently proposed by a new study focused on the genomic burden of 
rare CNVs that showed how deletions in NRXN1 have empirical thresholds for genome-
wide significance [32]. 
The same study observed empirical genome-wide thresholds also for duplication 
involving contactin 6 (CNTN6), a novel association for TS [32].  
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A very interesting gene has been linked to TS via CNV, a study discovered a TS family 
carrying a microdeletion in the first exon of dipeptidyl peptidase like 6 (DPP6) [33]. This 
gene may be promising because it is expressed in the striatum, an area of the central 
nervous system with a clear role in the pathology of TS [34]. DPP6 also influences 
dopamine levels and the dopaminergic pathway which is considered one of the major 
signaling cascade in TS. 
A final example is the case of micro-duplications in cholinergic receptor nicotinic alpha 
7 subunit (CHRNA7), a gene involved in fast signal transmission at synapses that is a 
major component of the brain nicotinic receptors, identified in 2 TS patients [35]. 
 
2.2.2 VNTRs and Tourette Syndrome  
 
VNTRs are usually defined as short sequences of nucleotides, usually up to 100 base pairs 
(bp), organized in multiple copies grouped together and oriented in the same direction. 
VNTRs are divided into microsatellites (1 to 6 bp) or mini-satellites (14 to 100 bp) based 
on the length of the repeated units. The presence of a VNTR within a gene or nearby the 
regulatory region of genes, might affect gene expression or the protein structure, thus 
leading to development of diseases.  
One of the most studied VNTR in Tourette Syndrome is linked to dopamine receptor D4 
(DRD4). DRD4 is a thoroughly studied gene in neuropsychiatric disorders, due to its 
pivotal role in regulating different brain functions such as the regulation of emotion, 
cognition and the modulation of neuroendocrine secretion [36]. This gene, located on 
chromosome 11p15.5, encodes for a G-protein coupled receptor, which inhibits adenylyl 
cyclase and it is known for encompassing a polymorphism consisting of a 48 bp VNTR 
[37, 38]. The most common VNTRs are the seven repeat units (a longer form of the gene), 
the four repeat units, and the two repeat units (a shorter form of the gene). It has been 
reported that the transmission of the long form of the gene (7 repeats) is over-transmitted 
in TS patients [39]. The same over-transmission of this VNTR has been subsequently 
observed in a different cohort of French-Canadian TS patients [40]. More recently, a 
family-based study on the 2x and 4x repeats revealed a significant transmission 
disequilibrium for both repeat-alleles [41].The authors speculated that the 2x repeat allele 
might play a protective role while the 4x repeat might confers risk. 
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The solute carrier family 6 member 3 (SLC6A3), also called DAT1, is another gene that 
has been associated with TS via VNTR. Coding for the dopamine transporter, it is a key 
component in the modulation of dopamine neurotransmission at the post-synaptic level. 
A genetic study showed that a 40 bp VNTR located in the 3′ untranslated region (3’UTR) 
of this gene is significantly associated with TS [42] and with increased tic manifestation 
[43].  
The study of monoamine oxidase A (MAOA) also led to promising results even though 
there have not been new reports since 2004. This gene is involved in the breakdown and 
inactivation of monoamine neurotransmitters, such as serotonin and dopamine. The 
presence of a VNTR in exon 1 was found to be significantly higher in TS patients 
compared to controls [44]. In a second study it has been observed that a VNTR in the 
promoter region is also associated with TS [40]. It is important to note that MAOA is 
located on chromosome X and since TS has a male-female ratio of four to one, genetic 
studies need to correct for it thus affecting statistical power. 
 
2.2.3 SNPs and Tourette Syndrome 
 
Single nucleotide polymorphisms (SNPs) are the most common types of genetic variation 
among people. It represents a variation in the DNA sequence that occurs at a frequency 
higher than 1% in which a single nucleotide of the genome differs between members of 
a biological species or paired chromosomes [45]. In every human genome there are 
millions of SNPs but most of them are neutral and do not have any biological 
repercussion. However, there are some that may alter gene expression or cause structural 
changes in the encoded proteins thus leading to diseases. 
Most of the TS genetic findings associated are conflicting since a lot of positive results 
have not been replicated in independent cohorts. Moreover, many genetic studies are done 
by individual labs with either small or medium sample size, which cannot easily reach 
statistical significance in a such complex genetic disorder. So below I will list these 
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2.2.3.1 Strong Positive Findings 
 
One the most robust finding is represented by the top signal of the first genome wide 
association study (GWAS) of TS [46]. In a sample of 1285 cases and 4964 ancestry-
matched controls, the SNP coded by rs7868992 was identified as the top hit (p = 1.85E-
6). It is located in an intronic region of collagen, type XXVII, alpha 1 (COL27A1). The 
same SNP was associated to TS also in another study comprising of 260 Chinese trios 
[47]. The transmission disequilibrium test (TDT) showed the preferential transmission of 
the rs7868992 as well as rs4979357, however these results did not survive correction for 
multiple testing [47]. 
Some of the top hits (n = 42) of the first GWAS have been subsequently followed up [48]. 
The meta-analysis identified rs2060546 on netrin 4 (NTN4) as the strongest signal 
(p=5.8E-7). This gene might play an important role in the development of the nervous 
system by promoting axon outgrowth and guidance. The meta-analysis observed a similar 
trend (susceptibility risk for TS) for 26 of the 42 SNPs investigated, thus corroborating 
the reliability of the GWAS findings. More recently, a study comprising of 240 TS 
patients (Danish cohort) and 1006 healthy controls attempted to replicate the same NTN4 
finding [49]. The analysis did not show any significant association but the subsequent 
meta-analysis that combined samples from the TS GWAS Replication Initiative (GGRI) 
and the first TS-GWAS yielded a significant signal (OR = 3.74, p = 0.00018). 
Before the publication of the first GWAS on Tourette Syndrome, the SLIT and NTRK 
like family member 1 (SLITRK1) gene was the most extensively studied. It regulates the 
growth of neurites during embryonic and postnatal development of the cortex, thalamus 
and the basal ganglia which are pivotal neuroanatomical area involved in TS pathology 
[50]. The first SLITK1 study, in 2005, identified a rare mutation (var321) in the 3′UTR of 
the gene, an area with a putative binding site for microRNA-189 [51]. Since the original 
discovery, several studies in various populations have attempted to replicate the 
association of SLITRK1 with TS but the results have been quite controversial. Indeed, 
many genetic studies failed to provided new positive findings as well as replicating the 
previous ones [52-57]. On the other hand, several genetic studies were able to provide 
support on the role of SLITRK1 in the development of TS [58-62]. 
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For instance, a family study performed on Canadian population detected a significant 
association between rs9593835 and TS [62]. The same SNP (rs9593835) has been 
positively replicated in a study performed on a Japanese population that found also an 
association of rs9546538 and rs9531520 with TS [60]. One more study performed on a 
large European population was also able to confirm the association between rs9546538 
and rs9593835 with TS [61]. Moreover, a targeted resequencing approach has identified 
four variants that confirm the involvement of SLITRK1 in the pathology [58]. 
One more largely investigated gene is the histidine decarboxylase (HDC). It was first 
discovered in a unique family where the father and all the affected off-springs had a 
variation that was causing a premature termination codon [59]. It was later on studied in 
a Chinese Han population that revealed no positive findings [63]. Lastly, a TDT test 
performed on 520 European detected an over-transmission of rs854150 and rs1894236 to 
be over-transmitted in patients [64], while a targeted resequencing approach identified a 
new deleterious variation that might increase TS risk [58]. Moreover, a HDC knockout 
mouse has also been proposed as a genetic model of TS [65, 66].  
The last example of a very deeply investigated gene is BTB (POZ) domain containing 9 
(BTBD9), which has been widely analyzed in TS leading once again to controversial 
results. The dispute is centered around rs4714156, rs9296249, and rs935727: one study 
on Canadian population showed an association of all those SNPs [67], but a second study 
on a Chinese Han population detected an association of only rs9296249 [68], while a third 
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2.2.3.2 Single Positive Findings 
 
Many other single nucleotide polymorphisms have been discovered and proposed as 
susceptibility factors in the development of Tourette Syndrome. In the following section 
they are grouped according to the different biological pathways that may or may not be 
involved in TS pathogenesis.   
 
2.2.3.2.1 Glutamate   
 
Several genes are linked to the glutamatergic pathway, thus supporting the theory of 
glutamate and its involvement in Tourette Syndrome [70]. 
For instance, is the case of cadherin 2, type 1, N-cadherin neuronal (CDH2).  It regulates 
the growth and navigation of axons, the correct function of synapses [71] as well as the 
traffic of glutamate [72]. A genetic study performed on a cohort of both OCD and TS 
patients detected a positive, but not significant, association of four SNPs with TS [73]. 
Although none of these SNPs were statistically significant, rs201333291 was the most 
interesting because it was found in 3 TS patients but not among the controls and because 
further studies showed that rs201333291 resulted in reduced CDH2 protein expression 
[73].  
Supporting the theory of glutamate is also the case of rs1805476 and rs1805502 located 
on glutamate receptor, ionotropic, N-methyl D-aspartate 2B (GRIN2B) linked to Tourette 
in a Chinese Han population study [74]. It encodes for the subunit 2 of the NMDA 
receptor channels and acts as agonist binding site for glutamate. It is expressed in the 
hippocampus, basal ganglia, and cerebral cortex where it acts as excitatory 
neurotransmitter receptor [75]. 
One more case is represented by rs5751876 located on the adenosine A2a receptor 
(ADORA2A) gene and rs2228079 situated on adenosine A1 receptor (ADORA1) which 
have been associated to Tourette in a Polish population study [76]. The heterodimer 
formed by the A1-A2 receptors regulates the striatal glutamatergic neurotransmission 
therefore an abnormal regulation caused by SNPs in these two genes might represent a 
risk factor for TS [77]. The A1 receptor is widely distributed in the brain, where it acts as 
an inhibitor of synaptic transmission and neuron hyperpolarization, while the A2 receptor 
DOI:10.14753/SE.2019.2338
- 22 - 
 
is highly expressed in the striatum, where it functions as facilitator of the transmitter 
release and as regulator of the sensorimotor integration into basal ganglia [78].  
 
2.2.3.2.2 Oxidative Stress  
 
One interesting theory about Tourette Syndrome is the involvement of oxidative stress. 
Indeed, few susceptibility genes are involved in the detoxification pathways, and it is 
possible to speculate and to factor in also oxidative stress in the occurrence of the 
pathology. However, further studies and more strong findings are needed to fully accept 
this hypothesis. 
The first gene involved in the theory is poly (ADP-ribose) polymerase 1 (PARP1) which 
encodes for a chromatin-associated enzyme that modifies various nuclear proteins by 
poly(ADP-ribosyl)ation. It has been reported that rs1805404 is susceptibility factor for 
TS [79]. 
The second gene around which the oxidative theory is built is X-ray repair complementing 
defective repair in Chinese hamster cells 1 (XRCC1), which is known to interact with 
PARP1 in the base excision repair pathway after oxidative stress. A study on Chinese 
Han population linked this gene to TS through rs25487 [80].  
The third and last gene is glutathione S-transferase pi 1 (GSTP1) which has been 
associated to TS in a Taiwanese study through rs6591256 [81]. GSTP1 is involved in the 
detoxification process by catalyzing the conjugation of many hydrophobic and 
electrophilic compounds with reduced glutathione [82]. 
 
2.2.3.2.3 Dopamine & Serotonin 
 
Compelling evidence (as also from genetic studies) supports the idea that both 
dopaminergic and serotoninergic pathways play a role in Tourette Syndrome [83] and 
there are some single positive finding falling under this theory.  
Some examples are the glial cell derived neurotrophic factor (GDNF), the solute carrier 
family 6 (neurotransmitter transporter) member 4 (SLC6A4) and the tryptophan 
hydroxylase (TPH2) genes.  
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GDNF has been recently associated to TS through rs3096140 [84]. It promotes the 
survival and differentiation of dopaminergic neurons and it prevents the apoptosis of 
motor neurons [85]. 
SLC6A4 (serotonin transporter) expression is controlled by the SERT-linked polymorphic 
region (5-HTTLPR), which consists of a 43bp (VNTR) in the promoter region that is 
characterized by a short (S) and a long (L) allele. It has been shown how rs25531, the 
long allele, might be associated to Tourette Syndrome [86]. The TPH2 gene codes for the 
tryptophan hydroxylase enzyme, which is responsible for the synthesis of serotonin in the 
brain [87] and a variant of this gene has been associated with TS [88]. 
 
2.2.4 Disentangling the Genetic Complexity of Tourette Syndrome 
 
It is important to pause for a moment and look again at the multiple positive genetic 
findings described above.  
It is not possible to not realize how difficult it is to study and to identify a positive 
association in a complex disorder like TS. It is one of the reasons that lead to the 
establishment of an extensive research network (TS-EUROTRAIN) able to dig in the 
genetic background of Tourette Syndrome with sufficient tools and resources to 
overcome issues like population stratification, sample size and statistical power [6]. It is 
very unlikely that one single variation might cause all the variety of symptoms that appear 
in the patients. In my opinion, the fragmentation of these findings resembles the genetic 
complexity of Tourette Syndrome and supports the theory that a combination of small 
effects leads to the manifestation of the phenotype. It is also important to notice that in 
most of the studies mentioned above, the genetic findings have not been yet replicated 
partly because they have been found in small samples that may suffer from population 
stratification. Moreover, not many of the SNPs findings have been supported by follow-
up experiments to actually check the biological relevance of the variations identified.   
Small sample size represents also a major problem in the TS dataset used for the genetic 
association study of my PhD project. In order to maximize the chances of finding 
something statistically significant, I decided to focus on the 3’UTR genes of TS candidate 
genes for the following reasons: 
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 there are few studies reporting association within the 3’UTR 
 the presence of SNPs in the 3’UTR might have an important biological relevance 
in case it is located within a miRNA binding site 
 the possibility to perform follow-up studies   
 
 
2.3 Epigenetic Background of Tourette  
 
Tourette Syndrome is not only about genetics.  
In the last years there has been a growing consensus that epigenetics might also contribute 
to the development of the pathology. Epigenetics usually refers to those changes, such as 
DNA methylation, histone modifications and microRNA regulation, in the gene 
expression or cellular phenotype that do not alter the sequence of the DNA [89]. Since 
these modifications are both cells and time specific it becomes extremely important to 
study not only the exact tissue involved in the pathogenesis of the disorder, but also at the 
correct time. Moreover, these modifications are usually dynamic and influenced by both 
internal and external stimuli [90].   
Tourette Syndrome clearly appears to be a good candidate for epigenetic mechanisms: 
symptoms appear and disappear based on the emotional status of the patients with a 
different intensity and frequency, and the time lapse of the disorders is scattered and 
different for every patient. 
It is known that external factors like psychological stress, maternal smoking during 
pregnancy, the age of the father, birth weight and exposure to medication in utero 
represent a risk for TS development [91]. The appearance of TS might be a consequence 
of a pediatric autoimmune neuropsychiatric disorder associated with streptococcal 
infection (the PANDAS hypothesis) [92]. Some direct links to Tourette Syndrome and 
DNA methylation or microRNA regulation have been recently reported [19].  
Epigenetic changes are cells specific and Tourette Syndrome is a neurodevelopmental 
disorder. The difficulty to access human brain samples represents a major drawback in 
the understanding of epigenetic alterations in TS pathophysiology and it makes the 
availability of animal models a key component in scientific studies. For these reasons, 
TS-EUROTRAIN Network [6] had 2 PhD projects focused only on the establishment of 
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new animal models of TS in order to have a direct access to brain tissues, during 
childhood and adolescence, involved in the pathology (see below).  
 
2.3.1 The role of DNA Methylation in epigenetic regulation 
 
DNA methylation is the predominant epigenetic modification in eukaryotic DNA. It 
refers to a covalent addition of a methyl (CH3) group to the 5’C of a cytosine residue 
located in area of the genome rich in cytosine-phosphate-guanine (CpG) dinucleotides. 
In the genome, there are stretches of DNA with a very high density of CpG dinucleotides 
(CpG islands) usually found in an unmethylated status [93]. In those area, it is possible 
to find approximately 70% of promoters, key regulatory regions in the modulation of 
genes transcription [94]. The CpG islands associated with promoters are usually 
conserved across species because of their role in transcriptional processes [95]. In 
particular, they regulate both the chromatin structure as well as the binding of 
transcription factors. Indeed, the addition of a methyl group to the DNA leads to the 
formation of a very tight structure (heterochromatin) usually wrapped around histones 
that is difficult to access for transcriptional factors and other regulatory units.  
DNA methylation represses transcription directly, by inhibiting the binding of specific 
transcription factors, and indirectly, by recruiting methyl-CpG-binding protein [96]. 
Moreover, at least in mammals, methylation of DNA is associated with other processes 
like genomic imprinting, X-chromosome inactivation, repression of transposable 
elements, aging, and carcinogenesis [97]. 
DNA methylation is catalyzed by a family of enzymes called DNA methyltransferases 
(DNMTs) which either create or preserve the methylation profile. In mammals, this 
family has three major members: DNMT1, DNMT3A and DNMT3B. These proteins 
have a very similar structure containing a catalytic C-terminal domain and a regulatory 
N-terminal domain. 
DNMT1 is a maintenance methyl-transferase that binds to hemi methylated DNA strand 
in order to preserve and restore the pattern of methylation after DNA replication processes 
[98]. Indeed, DNMT1 is located at the replication forks, where it binds the newly 
synthesized DNA and it catalyzes the reaction to restore the original methylation pattern 
[99]. In contrast, DNMT3A and DNMT3B are de novo methyltransferases capable of 
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originating a new pattern of methylation. DNMT3L is catalytically inactive but stimulates 
de novo methylation by binding to DNMT3A/B and it is also thought to be required for 
the establishment of maternal genomic imprints [100].  
On the other hand, DNA demethylation is catalyzed mainly by members of the ten-
eleven-transferase (TET) enzyme family through the hydroxylation of the methyl group. 
The reaction leads to the formation of 5-hydroxymethyl-cytosine (5-hmC) [101, 102]. 
The methylation of DNA usually involves a few percentage (between 3 and 7%) of the 
genomic cytosines, while the 5-hMC involves only 0.01–1% of all cytosines [103]. 
During development, differentiating cells undergo dynamic methylation changes at 
genome wide level before reaching the adult cell type. Similarly, the induction and 
differentiation of stem cells is followed by rapid changes in DNA methylation [19]. 
Moreover, DNA methylation results also in response to external factors like hormonal, 
metabolic or early childhood stress. It eventually leads to the silencing of gene expression. 
Same fallout has been observed in presence of toxic molecules or viral infections [102]. 
Epigenetic modifications do play a pivotal role in brain plasticity as well as different 
central nervous system processes: the differentiation of neuronal stem cells [104], the 
molecular, hormonal and behavioral response to environmental stimuli [105-107] and the 
plasticity of synapses [108]. It is therefore important to establish and also to maintain the 
cell-specific methylation pattern during the early stage of brain development [109]. 
To further support the importance of DNA methylation in brain development there are 
the findings of a dynamic expression of DNMT3A and DNMT3B [110] as well as the 
appearance of neuronal deficits in case of mutation in the methyl-CpG-binding protein 2 
(MECP2) [111, 112]. Indeed, mutations in MECP2 have been associated to autism 
spectrum disorder and Rett Syndrome  [113-115].  
Moreover, different studies found evidences of abnormal methylation levels linked to the 
manifestation of neurological symptoms in Schizophrenia [116, 117], Parkinson’s disease 
[118, 119] and, more recently, Tourette Syndrome [120]. 
However, most of the studies published so far are performed on small sample size or on 
surrogate tissues because it is not possible to access the brain tissue at the time of the 
manifestation of tics. In conclusion, there is a major need for more studies to untangle the 
involvement of epigenetics in the development of neurological disorders. 
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2.3.1.1 DNA Methylation and Tourette Syndrome 
 
To date, very few papers have studied methylation changes in relation to TS. There is a 
study that provides a direct link between DNA methylation of DRD2 and TS [120]. 
Indeed, the study was able to show a positive correlation between high methylation level 
of the DRD2 gene and the severity of tics. However, the study involved a group of adult 
patients and detected also increased methylation along with age and antipsychotic 
medication [120]. The authors are speculating that hyper-methylation of DRD2 might 
lead to dysfunction in the dopaminergic system, thus leading to an enhanced locomotor 
activity throughout the indirect CSTC pathway. 
The second study is the first Epigenome Wide Association Study (EWAS) investigating 
DNA methylation differences between controls and patients from the Netherlands Twin 
Registry with tic phenotype [121]. It showed an enrichment of differentially methylated 
neural genes previously linked to neuropsychiatric disorders or with brain specific 
functions (see below).  
 
2.3.2 The role of microRNAs in the regulation of gene expression 
 
The microRNAs (miRNA) are a small, non-coding RNA molecule found in plants, 
animals and some viruses, which function in transcriptional and post-transcriptional 
regulation of gene expression. 
Most of the miRNAs are highly expressed in the human brain, where they exert their 
function by modulating cell survival, neurite projection, and synaptic plasticity. It is not 
surprising, given their expression and function, that miRNAs have an important role in 
many psychiatric disorders [122]. 
The biogenesis of microRNAs (Fig. 2) is a process that starts in the nucleus and ends in 
the cytoplasm with a cleavage point in each nuclear localization. The final product is a 
single strand with a length of ~22 nucleotide that subsequently affects the expression of 
genes. In the first step, the RNA Polimerase II transcribes the coding gene of a miRNA 
into a prototype (pri-miRNA) with a very distinctive hairpin structure and a terminal loop 
[123]. Subsequently, during the first cleavage step, the hairpin structure is cut originating 
the pre-miRNA, a prototype with a length of ~70 nucleotide which is then exported into 
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the cytoplasm [124]. In the cytoplasm, the pre-miRNA is cleaved for the second time to 
originate a precursor with a length of ~22 nucleotide, generally called miRNA-miRNA 
duplex. One strand of this duplex is placed into a large multi-protein miRNA 
ribonucleoprotein complex (RISC complex), while the remaining strand is degraded. The 
strand incorporated into RISC, guides the subunit to a messenger RNA (mRNA). Based 
on a base-pair interaction, a 6–8 nucleotide domain located at the 5′ end of the miRNA, 
the miRNA might bind the 3’UTR of a mRNA leading to a reduction of the gene 
expression through the repression of translation or the degradation of mRNA [125]. 
Therefore, the presence of SNPs in the 3′UTR could be important because it might either 
destroy or create a binding site for miRNAs:  
 
a. it can partially or completely disrupt the miRNA binding site, thus resulting in 
higher expression of the target gene 
b. it could enhance the binding of a miRNA to the 3′UTR region  
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Fig. 2 from  [19] 
The biogenesis of miRNAs: MicroRNA (miRNA) genes are transcribed as primary 
miRNAs (pri-miRNAs) by RNA polymerase II (Pol II) in the nucleus. The pri-miRNAs 
are subsequently cleaved to originate pre-miRNAs, which are then exported to the 
cytoplasm and cleaved to produce a miRNA duplex. One strand of the mature miRNA 
is loaded into the miRNA-induced silencing complex (RISC) and it leads to mRNA 
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2.3.2.1 MicroRNAs and Tourette Syndrome 
 
The finding of Abelson et al. 2005 [51] is the only genetic study with a direct link between 
miRNA and Tourette Syndrome. In this paper, the author reported an interaction between 
mir-189 and SLITRK1 in TS patients carrying one noncoding sequence variant, var321, 
that changes one nucleotide in the sequence of the miRNA binding site (G:U into A:U). 
This variation results in a very highly conserved binding site for microRNA and it allows 
mir-189 to strongly repress SLITRK1 protein expression [51]. 
It had been 10 years before the paper of Rizzo et al. 2015. The study is focused on miRNA 
expression profile in serum of six TS patients and three controls and it showed a 
significant under-expression of mir-429 TS patients [126]. 
 
2.3.3 Increased Effort to Study Methylation and Tourette Syndrome 
 
It appears evident that epigenetic studies and Tourette Syndrome have a very long way to 
go and, as previously said, TS might resemble some epigenetic peculiarities. Indeed, the 
symptoms wax and wane based on the stress level of the patients and so do DNA 
modifications, which can occasionally be very dynamic and change based on 
environmental stress. 
It will never be a possible to directly access the human brain of those young patients. 
Therefore, scientific studies will always have to rely on animal models since the 
epigenetic changes are tissue and time specific. It is a field where there is still a lot of 
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2.4 Animal Models 
 
The use of an appropriate animal model to study Tourette Syndrome still represents a big 
challenge. Indeed, it is very difficult to reproduce in a single animal model all the different 
clinical manifestations observed in TS patients (for detailed review of TS animal models 
see [127]). However, they represent the only option to perform invasive biological studies 
in a living organism. 
Animal models are usually characterized by face validity (ability to show similar 
symptoms to the patients' ones), construct validity (model developed according to a 
rationale matching the pathological hypothesis), and predictive validity (the model 
responds to a treatment similarly to patients).  
The existing animal models of TS available today do not possess all the three validity 
components but are mostly based on a single component: 
 
1) based on genetic findings 
2) modelling the tic phenotype 
3) resembling the TS sensorimotor gating deficit 
4) based on environmental factors  
 
2.4.1 Abnormal Involuntary Movements (AIMs)  
 
The availability of an animal model is pivotal in the study of many neurological disorders 
where it is not possible to access brain tissue involved in the pathology. The model used 
in this PhD project is called abnormal involuntary movements (AIMs) and it was 
established by our collaborators at Boehringer Ingelheim pharmaceutical company, in 
Germany.  
This type of model is widely used to study Parkinson’s disease (PD) where the chronic 
administration of L-DOPA often results in the development of AIMs, an important 
clinical symptom that affects almost 90% of PD patients. However, the pathogenic 
mechanisms underlying AIMs are not yet understood.  
Previous studies showed that chronic L-DOPA administration altered principally the 
dopaminergic pathway but also several other neurotransmitter systems [128-130]. Indeed, 
DOI:10.14753/SE.2019.2338
- 32 - 
 
the administration of L-DOPA activates striatal dopamine D1 receptors (DRD1), 
resulting in the overstimulation of the “direct” pathway (see above) [131, 132]. The 
hypersensitivity to dopamine sparks a number of downstream signaling cascades (cyclic 
AMP (cAMP)-activated protein kinase A (PKA) [133, 134], the phosphatase inhibitor 
DARPP-32 [134, 135], and the ERK1/ERK2 (ERK1/2) kinases) [136, 137] involved in 
the manifestation of locomotor activity [138, 139].  
 
2.4.2 Translating AIMs in Tourette Syndrome 
 
Even though the AIMs animal model is very well accepted to study PD, it provides the 
same pathophysiological condition that leads to the manifestation of tics observed in TS. 
Indeed, the hypersensitivity to dopamine is a condition observed in both PD and TS 
patients. Therefore, it has been decided by our collaborators at Boehringer Ingelheim, to 
translate the AIMs animal model into juvenile rats since Tourette Syndrome is a 
neurodevelopmental disorder to better study the biological mechanism behind tics as well 
as to test new drugs (such as Riluzole) able to reduce the manifestation of locomotor 
activity. 
In order to mimic TS pathological conditions, rats were unilaterally injected in the medial 
forebrain bundle, an area of the brain enriched with projection of dopaminergic neurons 
of substantia nigra, with a chemical toxin named 6-hydroxidopamine (6-OHDA). Once 
injected in the brain, the 6-OHDA is selectively absorbed by those neurons expressing 
the dopamine transporters, such as dopaminergic and noradrenergic neurons, which carry 
the toxin inside the dopaminergic neurons. The toxin starts to accumulate in the 
dopaminergic neurons and it eventually leads to the production of reactive oxygen species 
and to cell death. The absence of dopaminergic inputs results in dopamine 
hypersensitivity, the same pathological condition observed in TS patients. The subsequent 
oral administration of L-DOPA, a precursor of dopamine, triggers the appearance of 
abnormal involuntary movements (AIMs). 
On the other hand, Riluzole has been suggested as a candidate drug to treat AIMs since 
previous studies on rodents provided evidence for the efficacy of Riluzole in the treatment 
of AIMs [140-142]. As for human studies, Riluzole showed anti-dyskinetic effects in a 
small pilot study [143], but it was ineffective in another clinical trial [144]. However, the 
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molecular mechanisms of Riluzole in protecting from the manifestation of AIMs are still 
unknown. It has been hypothesized that Riluzole might exert its function by acting as a 
blocker of glutamate, as inactivator of voltage-dependent sodium channels, as obstructer 
of intracellular processes. 
In this PhD project we decided to use the AIMs animal model to study both RNA and 
DNA of brain to shed some light on the speculated relevance of DNA methylation 
changes in the development of locomotor activity and to identify drug targets (see below). 
 
2.5 TS-EUROTRAIN Network 
 
TS-EUROTRAIN Network was established with the idea of training 12 Early Stage 
Researchers (ESRs) to collaborate on the investigation of Tourette Syndrome and to share 
the knowledge deriving from imaging studies, animal models, bioinformatics analyses 
and genetic studies.  
 
2.5.1 TS-EUROTRAIN Tasks 
 
The investigation of environmental and genetic factors in TS:  
 
 identify genes and gene pathways that influence the pathogenesis and clinical 
course of TS  
 explore the involvement of epigenetic phenomena in the onset of symptoms of TS  
 explore the complex interaction between the environment, autoimmunity and 
genetics  
 
The investigation of the neurobiological mechanisms of TS: 
 
 investigate the neurocognitive pathways underlying the broad TS phenotype  
 establish patterns of multivariate brain activation and connectivity for TS 
through neuroimaging studies  
 investigate the role of the glutamate metabolism in TS   
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To translate research findings into clinical applications:  
 
 define endophenotypes and prediction models for TS  
 investigate the pathophysiology of the psychotropic compounds that are already 
in use or under clinical trials for TS  
 identify novel targets for drug therapy for TS and related comorbidities  
 
The following PhD work results from an extensive collaboration with several of the PhD 
students recruited in the TS-EUROTRAIN Network: 
 
1) the animal model was established by our collaborators at Boehringer Ingelheim, 
Biberach, Germany. 
 
2) the Epigenome Wide Association Study (EWAS) was done with our collaborators 
at VU Amsterdam University, Amsterdam, The Netherlands. 
 
3) the transcriptome analysis and the molecular landscape was built with our 
collaborators at Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands. 
 
I am going to focus on and to describe mainly the parts of the project I was actively 
working on and gave my substantial contribution. The full description of the methods and 
results (as well as a proper background) of the projects discussed in this PhD, that are not 
my expertise, may be found in the respective manuscripts. The only exception involves 
the methods of the animal model. I was not the one who established it but the model has 
not been published yet, therefore, I am going to provide more details about it in the 
methods/results section.  
I was also partially involved in the statistical analysis of RNA and DNA data even though 
I was not the one who did the substantial amount of work since I am not an expert in those 









1) Identify new genetic variations that may represent risks for Tourette Syndrome by 
focusing on the 3’UTR of TS candidate genes. 
 
 
2) Shed some light on the role of DNA methylation in the development of Tourette 
Syndrome by performing the first ever Epigenome Wide Association Study 




3) Study the transcriptome of striatum of an AIMs animal model to build a molecular 
landscape aimed to unravel the molecular mechanism of action of Riluzole. 
 
 
4) Study the methylation pattern of striatum of AIMs animal model at the genome 
level to identify which changes occur after the administration of L-DOPA or the 
injection of 6-OHDA. 
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4.1 Genetic studies of Tourette Syndrome 
 
4.1.1 In silico work 
 
I originally obtained a list of TS candidate genes by performing a literature research on 
PubMed using the terms “Tourette Syndrome” or “TS” combined with “gene” or 
“genetics” and also by using a software called HugeNavigator  [145]. Subsequently, I 
focused the attention on SNPs which are located in the 3’UTR regulatory sequences of 
TS candidate genes and also predicted (using the PolymiRTS database) to alter the seed 
sequence of miRNAs binding site. Thirty such SNPs were selected and successfully 
genotyped using our customized TaqMan® OpenArray® genotyping chips (Table 2). 
 
 
Table 2: List of SNPs selected for the OpenArray® genotyping chip 
Gene Gene name SNP Minor Allele 
Frequency 





  0.49 (A) 
 
ACP1 Acid phosphatase 1, 
soluble 
rs6855 




Cannabinoid receptor 1 rs4707436   0.24 (A) Yes 





rs1062072   0.46 (A) Yes 
rs2530310   0.42 (T) Yes 
rs2530311   0.47 (A) Yes 





rs165599   0.47 (G)  Yes 
rs165728   0.16 (C)  
DRD2 
 
Dopamine receptor D2 rs6276   0.48 (T) Yes 
rs6278   0.20 (A) Yes 
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Glial cell derived 
neurotrophic factor 
rs2973051    0.34 (C) Yes 
rs3749692    0.46 (A) Yes 




  0.14 (G) 
Yes 
ILR1N Interleukin 1 receptor 
antagonist 
rs4252041 







rs1044729    0.34 (C)  
rs17158195    0.13 (T)  
rs7795011    0.46 (G)  
LHX6 
 
LIM homeobox 6 rs3750486    0.08 (A) Yes 
rs74370188    0.01 (A) Yes 
MEIS1 Meis homeobox 1 rs72824830   0.02 (G) Yes 
NTN4 Netrin 4 rs1052651    0.38 (A) Yes 
rs8699    0.43 (G) Yes 
SLC6A3 
 
Solute carrier family 6 
member 3 
rs11564774   0.23 (G)  
rs7732456   0.07 (C)  
SLITRK1 
 
SLIT and NTRK like 
family member 1 
rs3737193    0.03 (G) Yes 
rs41557622    0.02 (T) Yes 




DNA samples are part of the TSGeneSEE consortium collection (the Tourette Syndrome 
Genetics - Southern and Eastern Europe Initiative), consisting of 148 families and 290 
case-control samples from Hungary, Italy, Poland, Greece and Albania. The assessment 
was performed by on-site clinicians using the tools provided by the TS Association 
International Consortium for Genetics. Diagnosis of TS was ascertained according to 
DSM-IV-TR criteria for Italy, Hungary, Albania and Greece, and DSM-IV for Poland. 
The collection of TSGeneSEE samples was coordinated and approved by the Democritus 
University of Thrace Research Ethics Committee, and a written informed consent was 
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obtained from all participating individuals or their parents. The average age at onset of 
the children (154 males, 152 females) involved in the study was 5.7 ± 2.19 years. 
Regarding the Transmission Disequilibrium Test (TDT), the sample consisted of “trios” 
where we have records of the complete family (child, mother and father) and the 
“incomplete trios” where one of the parents is missing from the dataset. The combined 




Genotyping of samples was performed using TaqMan® OpenArray® Genotyping System 
[146]. The processing of raw data was performed by the TaqMan® Genotyping Software 
(Applied Biosystems®). As a quality control step, 10% of samples were re-genotyped to 
avoid any batch effects and samples that failed to pass the genotyping rate of 90% were 
removed from the analysis. The final analysis consisted of 141 families (full and 
incomplete trios) and 266 samples (141 cases, 125 controls).   
 
4.1.4 Statistical Analysis 
 
Standard case-control association analysis was conducted in PLINK [147] using χ2 test 
comparing SNP frequencies within cases to that of controls. To avoid artifacts that might 
arise due to population structure we performed basic χ2 association with respect to TS 
separately for the different populations. The individual population association results 
were further meta-analyzed using the METAL software in a case-weighted fixed-effect 
model on p-values [148]. To correct the results for multiple testing 100,000 permutations 
were applied with the Monte Carlo Permutation (MCPerm method) [149].  
Family-based association was performed using the family-based Transmission 
Disequilibrium Test (TDT) option in PLINK software [147]. Families were checked for 
Mendelian errors and samples with an error rate above 10% were discarded from further 
analysis. Empirical significance levels were generated with PLINK using max (T) 
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4.1.5 Real-Time PCR 
 
On the same dataset that I used for the 3’UTR Open Array, I also performed genotyping 
of some of the candidate genes by Real-Time PCR. Table 3 shows the SNPs investigated. 
 
Table 3: List of SNPs analyzed by Real-Time PCR 
Gene Gene name SNP  Genotype 
GDNF 
 









SLC6A3 Solute carrier 
family 6 member 3 
rs27072 C/T 
TNF Tumor necrosis 
factor 
rs361525 A/G 
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The subjects in this study were participants in the NTR biobank Project. The analysis 
consisted of 1678 individuals (twins, siblings, and parents) from 1057 families [121]. 
 
4.2.2 Infinium HumanMethylation450 Bead Chip Kit (Illumina 450K) 
 
DNA methylation was assessed with the Infinium HumanMethylation450 Bead Chip Kit 
Array which covers 17 CpG sites on average per gene distributed across the promoter, 
5'UTR, first exon, gene body, and 3'UTR.   
 
4.2.3 Statistical Analysis 
 
EWAS (epigenome-wide association study) was performed using linear regression under 
an additive model correcting for principal components and covariates and CpG sites with 
p-value < 1.2*10-7 were considered statistically significant [121]. 
 
4.2.4 Enrichment of Gene Ontology terms 
 
The gene ontology enrichment analysis was performed by ranking all the methylation 
sites based on their p-value and the resulting ranked gene list was supplied to the online 
software tool Gorilla [150]. False Discovery Rate (FDR) q-value < 0.05 was considered 
for a GO term to be statistically significant. The literature research to investigate the 
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4.3 Animal model exhibiting abnormal involuntary movements (AIMs)  
 
The animal model (Fig. 3) was established by our collaborators at Boehringer Ingelheim, 
Biberach, Germany.  
Fig. 3: Schematic diagram of the protocol employed including the time course of the 
experiment and the different assays that were used. 
 
4.3.1 Stereotaxic surgery 
 
The rats underwent stereotaxic surgery with 6-hydroxydopamine (6-OHDA) at post-natal 
day (PND) 21. Once injected in the brain, the toxin starts to accumulate in the 
dopaminergic neurons and it eventually leads to the production of reactive oxygen species 
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4.3.2 Animal treatment 
 
The treatment administration (three times a week) started two weeks after the surgery, 
and the animals were randomly located into three groups (n = 12). The first group was 
chronically administered with a solution of L-DOPA (orally). The second group (control) 
was administered with only saline. The third group was chronically administered with L-
DOPA + Riluzole, a GABAergic/antiglutamatergic drug. 
 
4.3.3 Phenotype scoring 
 
During every treatment administration, rats were individually observed for 1 minute every 
20 minutes and abnormal involuntary movements (AIMs) of the limb, mouth, and body 
axis were scored on a scale from zero to four (0 = absent; 1 = occasional; 2 = frequent; 
3 = continuous but interrupted by sensory distraction; 4 = continuous, severe, not 
interrupted by sensory distraction) [151]. 
 
4.3.4 Samples extraction 
 
At post-natal day 53 (PND 53), the rats were administered one final treatment and 
sacrificed 2 hours later by a guillotine. The brain was removed, lesioned and non-lesioned 
striata were extracted, frozen in liquid nitrogen, and stored at – 80°C. 
 
4.3.5 RNA sequencing and data analysis  
 
Total RNA was extracted from striatum tissue from eight animals of each group using the 
QiagenAllPrep Kit (Qiagen), according to the manufacturer’s instructions. RNA was 
quantified using the NanoDrop 1000 Spectrophotometer and Bioanalyzer 2100 (Agilent). 
Samples with RIN value above 8.0 were used for transcriptome analysis. Library 
preparation for sequencing  was done using 200 ng of total RNA input with the TrueSeq 
RNA Sample Prep Kit v3-Set B (RS-122-2002, Illumina Inc, San Diego, CA) and the 
sequencing was then performed as 78 bp, single reads and 7 bases index read on an 
Illumina HiSeq3000 instrument using the TruSeq SBS Kit HS- v3 (50-cycle) (FC-401-
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3002, Illumina Inc, San Diego, CA). Statistical analyses were performed using R (www.r-
project.org) and the Bioconductor package limma-voom  [152]. The Benjamini-Hochberg 
method was used to correct for multiple testing, and only protein-coding genes with 
adjusted P-value < 0.01 were used for further analyses.  
The upstream regulator and gene enrichment analyses were done using Ingenuity 
Pathway Analysis (IPA) (https://www.qiagenbioinformatics.com/products/ingenuity-
pathway-analysis/). For each upstream regulator, IPA calculates a p-value of overlap 
(measuring the statistical significance of the overlap between the dataset genes and all 
genes that are regulated by the upstream regulator) and a z-score (reflecting the inhibition 
or activation of the upstream regulator-dependent effects on target gene expression). 
 
4.3.6 qPCR validation of selected CREB1 targets  
 
To check the reliability of the RNA sequencing data, we performed qPCR on 10 randomly 
chosen CREB1 target genes (Table 4). 100ng of RNA were reverse-transcribed to cDNA 
using the RT2 First Strand Kit (Qiagen, Cat. number 330404) according to the 
manufacturer’s instructions. Three-step qPCR (95°C for 10min, followed by 40 two-step 
cycles of 95°C for 15s, 60°C for 30s, and the generation of melting curves from 70 °C to 
95 °C; Rotor-Gene Q 1000, Qiagen) was performed using RT² SYBR Green ROXTM 
qPCR Mastermix (Qiagen, Cat. number 330521) and RT2 qPCR primer Assays provided 
by Qiagen. The housekeeping genes Bcap29 and Cdkn1b were used as reference for 
normalization of gene expression, and a Student’s t-test was used to assess statistical 
significance. 
 
Table 4: List of the gene and the primers (RT² qPCR Primer Assay by Qiagen) used for 
the qPCR validation experiment of mRNA data 
Gene 
Symbol 
Catalog number RefSeq Accession  
JUN PPR53221A NM_021835.3 
NPAS4 PPR52619A NM_153626.1 
GPR3 PPR52464A NM_153727.1 
NR4A3 PPR51343E NM_017352.1 
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PVR PPR44991A NM_017076.2 
ATF3 PPR44403B NM_012912.2 
REM2 PPR06549B NM_022685 













Table 4 from [151] 
 
4.3.7 Reduced Representation Bisulfite Sequencing (RRBS) 
 
Reduced representation bisulfite sequencing (RRBS) is a high-throughput technique used 
to analyze genome-wide DNA methylation profiles at the single nucleotide level of 4 
million CpGs (https://www.diagenode.com/en/p/premium-rrbs-kit-x96-96-rxns). In 
human, mouse and rat research, the protocol provided by Diagenode allows to replicate 
and compare DNA methylation levels in different experimental groups at an affordable 
price. Given the several experimental groups included in the methylation studies (some 
of which are not included in this PhD dissertation) we decided to use this particular 
protocol. 
 
4.3.8 RRBS protocol 
 
Striata from rodent animal models were processed using Premium RRBS kit x24 
(Diagenode). DNA was extracted using AllPrep DNA/RNA/miRNA Universal Kit 
(Qiagen). DNA fragmentation was checked on 1% agarose gel and only high-quality 
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DNA was used for preparation of Reduced Representation Bisulfite Sequencing libraries 
using Premium RRBS kit (Diagenode). 
Briefly (Fig. 3), 100ng of DNA was digested with MspI restriction enzyme which cuts at 
C^CGG sites regardless of the methylation status. Subsequently, the samples were treated 
with an enzyme that adds flanking ends and during this reaction, some spike in control to 
check the bisulfite conversion efficiency was also added. In the next step, a specific string 
of adaptors (6 base pair) was added to each sample followed by a size selection of the 
fragments (200-1200 bp). Sample concentration was then checked by quantitative PCR 
and up to 6 samples were pooled together using RRBS pooling algorithm provided by 
Diagenode. The software compares the Ct values and it calculates their relative 
concentrations 2^(-dCt). Bisulfite conversion was performed on pooled samples, in this 
step unmethylated cytosine is converted into uracil while methylated cytosine remained 
cytosine. Libraries were then ready for a quantification step followed by an enrichment 
PCR. Finally, the enriched PCR products were recovered, and the concentration was 
measured by Qubit dsDNA HS Assay (Life Technologies). The library profile was 
checked on Bioanalyzer 2100 (Agilent) before being sequenced on Illumina HiSeq2000. 
 
4.3.9 RRBS data analysis  
 
Illumina reads were quality checked with the FastQC (v0.10.0) software. The reads were 
trimmed by trimgalore (v0.4.0) and mapped to rn6 genome using Bismark (v0.14.3.) 
tolerating one non-bisulfite mismatch per read (-n 1 option). After mapping, the sorted 
sam files were used by methylKit (v1.0.0) for further analysis. First, methylated and 
unmethylated Cs in CpG context were checked and Cs with <=10 reads were used for 
further analyses. Similarity of samples were checked by pairwise Pearson’s 
correlations. Differentially methylated sites (DMSs) were considered significant only 
after both overdispersion correction and Chi square test with q <0.01. DMSs were 
annotated according to the type of genomic region (promoter, exon, intron, intergenic or 
CpG islands, shores, others). Hypo and hypermethylated genomic positions were further 
annotated to obtain the nearest ENTREZ and RefseqIDs, Gene Names, etc.). 
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Fig. 4: Reduced Representation Bisulfite Sequencing (RRBS) protocol workflow. 
The first step of the protocol is DNA extraction followed by a step of enzyme 
digestion and adaptor ligation. The samples are then selected based on the size (200-
1200 bp). Samples undergo bisulfite conversion, sequencing and data analysis to 
identify genome wide methylation changes.  
  
DNA Extraction
MSPI digestion -> CCGG 










5.1 Genetic studies of Tourette Syndrome 
 
5.1.1 Genetic variation identified by meta-analysis 
 
Table 5 shows the top results (p < 0.1) from the meta-analysis which lead to the 
identification of two significant SNPs that might represent risk factors for TS. The 
strongest signal was rs3750486 (p = 0.021) in the LHX6 gene, while the other significant 
SNP was rs7795011 (p = 0.029) in IMMP2L. Notably, the findings did withstand multiple 
correction tests.  
 
Table 5: List of the top hits (p-value < 0.1) of the meta-analysis 
Gene SNP 1stAllele 2ndAllele Frequency of affected allele P 
LHX6 rs3750486 A G 0.1075 0.021* 
IMMP2L rs7795011 T G 0.5483 0.029** 
AADAC rs1042201 A G 0.4648 0.077 
GDNF rs2937051 T C 0.6952 0.095 
*permutation p = 0.00136 **permutation p = 0.00935 
 
5.1.2 Over-transmission of alleles in TS patients  
 
Similar to the meta-analysis, we performed TDT on parent-child trios within each 
individual population as well as for the complete TSGeneSEE dataset (141 families). 








Table 6:  The results of the TDT test with a focus on the top hits of the meta-analysis. 
Ov.T = over-transmitted allele, T:U = transmitted:untransmitted, χ2 = chi-square value, 














 (9 trios) 
 
GENE SNP Ov.T T:U χ2 P Ov.T T:U χ2 P Ov.T T:U χ2 P Ov.T T:U χ2 P 
AADAC rs1042201 G 9:8 0.059 0.808 G 27:13 4.9 0.027   5:5 0 1 A 3:0 3 0.083 
GDNF rs2973051 C 10:8 0.222 0.637 C 18:16 0.118 0.732 T 8:7 0.067 0.796 C 6:3 1 0.317 
IMMP2L rs7795011 G 11:7 0.889 0.346 G 25:16 1.976 0.156 G 7:6 0.077 0.782 T 8:0 8 0.005 




When looking at individual populations, rs3750486 in LHX6 showed a slight but not 
significant over-transmission of the A allele in the Polish population (p = 0.025, χ2 = 5.0) 
and a significant transmission of the G allele in the Italian population (p = 0.002, χ2 = 
9.941) which remained significant also after 1000 permutation tests (p = 0.037). For 
rs7795011 in IMMP2L, we observed a nominally significant over-transmission of the T 
allele in the Greek population (p = 0.005, χ2 = 8.0) which withstands 1000 permutations 
test (p = 0.028). For rs1042201 at AADAC we also found nominally significant over-
transmission in the Italian population (p = 0.027, χ2 = 4.9). 
However, the indication obtained from individual population changes dramatically when 
we analyzed the full TSGeneSEE dataset (all 141 families) which consists of full trios 
and incomplete trios (Table 7). 
 
Table 7: Results of the TDT test performed on the full TSGeneSEE dataset (141 
families) with a focus on the top hits of the meta-analysis 
Gene SNP Ov.T T:U χ2 P Perm 
AADAC rs1042201 A 31:16 4.787 0.029 0.524 
GDNF rs2973051 C 41:37 0.205 0.650 1 
IMMP2L rs7795011 G 44:39 0.301 0.583 1 
LHX6 rs3750486 G 7:3 1.6 0.206 0.999 
Ov.T = over-transmitted allele, T:U = transmitted:untransmitted, χ2 = chi-square value, 
P = unadjusted p-value, Perm = 1000 permutations p-value 
 
Indeed, the results of the TDT test on the full dataset show that only allele A of rs1042201 
at AADAC is over-transmitted in TS patients (p = 0.029, χ2 = 4.787) even though the 
signal does not survive correction for multiple testing.  
It is important to note that AADAC gene is the top signal of both the meta-analysis and 







5.1.3 Results of the other genetic variations analyzed  
 
Table 8 shows the results of the genotyping performed by real-time PCR on the 
TSGeneSEE dataset while Table 9 shows the results of the TDT test. 
 
Table 8: Results of the genotyping experiments done by Real-Time PCR 
Gene SNP P-value 
GDNF rs1549250 0.320 
GDNF rs2910702 0.385 
WFS1 rs1046320 0.386 
TNF rs361525 0.415 
WFS1 rs1046322 0.424 
SLC6A3 rs27072 0.601 
GDNF rs11111 0.692 
GDNF rs1981844 0.937 
GDNF rs3812047 0.946 
GDNF rs2973033 0.962 
 
As shown in Table 8, we did not find any significant results in the case-control association 
















Table 9: Results of the TDT test of the genes previously analyzed by Real-Time PCR 
Gene SNP Ov.T T:U χ2 P-value 
SLC6A3 rs27072 T 37:26 1.921 0.166 
GDNF rs1549250 C 48:41 0.551 0.458 
WFS1 rs1046320 A 49:42 0.539 0.463 
GDNF rs3812047 C 20:16 0.444 0.505 
GDNF rs2910702 C 34:29 0.397 0.528 
WFS1 rs1046322 G 18:15 0.273 0.601 
TNF rs361525 G 12:10 0.182 0.670 
GDNF rs11111 C 37:34 0.127 0.722 
GDNF rs2973033 T 30:28 0.069 0.793 
GDNF rs1981844 G 25:24 0.020 0.886 
Ov.T=over-transmitted allele, T:U=transmitted:untransmitted, χ2=chi-square value 
 
The real-time PCR emphasizes one more time how difficult it is to find any significant or 
positive findings when operating with small and mixed samples. One of the aims of TS-
Eurotrain Network is to solve this problem by combining datasets from European 


















5.2 Epigenetic studies of Tourette Syndrome 
 
5.2.1 DNA methylation profile in the blood of TS patients: an EWAS study 
  
Epigenome-wide association study (EWAS) allows the identification of differentially 
methylated patterns likely associated to a phenotype of interest. We used this approach to 
investigate a possible correlation between methylation levels and the manifestation of 
tics. Figure 5 shows the overall distribution of genome-wide methylation level for the 
individuals (188 cases and 1490 controls) included in the study.  
 
Fig. 5 from [121] 
The figure represents the methylation status (min = 0, max = 1) of the CpGs analyzed in 
the study. 
 
The methylation status of a CpG is usually recorded as β-value that stretches from zero 
to one respectively for completely un-methylated and methylated status. By looking at 




at a specific time and it is quite normal to detect CpGs in either fully methylated or non-
methylated status. 
The EWAS did not detect any significant CpG site (Fig. 6) associated with the tic 
phenotype. However, it was able to identify 57 CpG sites (Table 10) with a p-value < 
0.0001. The permutation test (p < 0.05) shows that these CpG sites are not random and 
might have some relevance for the development of the pathology.  
 
 
Fig. 6 from [121] 
The figure depicts the Manhattan plot of the CpGs analyzed in the study. The red line 
represents the genome-wide threshold. The top CpG sites are highlighted in green. 
 
 
It is not surprising to not find any significant CpGs because we need to remember that the 
samples have a mixed phenotype (severity and duration) therefore to reach statistical 
significance the analysis would need more samples, both cases and controls, with a more 
selective phenotype. To achieve a good sample size is an issue that is also hampering the 
genetic studies since it is very difficult to collect a proper dataset of samples and there are 






































































































































































































































































































































































Table 10 from [121] 
 
5.2.2 Enrichment analysis of the annotated CpGs  
 
The gene ontology enrichment analysis done using the 57 CpGs listed in Table 10 
revealed a great number of GO terms significantly enriched [153]. The GO Processes 
analysis pointed towards developmental process (GO:0032502, FDR q-value = 2.69E-
12), cellular developmental process (GO:0048869, FDR q-value = 1.96E-12), single-
organism developmental process (GO:0044767, FDR q-value = 2.22E-12). It also picked 




projection guidance (GO:0097485, FDR q-value = 5.11E-08), axon guidance 
(GO:0007411, FDR q-value = 4.89E-08), neuron differentiation (GO:0030182, FDR q-
value = 6.24E-08). The GO component analysis points towards cell junction 
(GO:0030054, FDR q-value = 1.09E-05), neuronal structure (GO:0097458, FDR q-value 
= 1,78E-04), synapse part (GO:0044456, FDR q-value = 1.39E-03), postsynaptic density 
(GO:0014069, FDR q-value = 3.87E-03) and dendrite (GO:0030425, FDR q-value = 
1.05E-02).  
The GO component analysis gave also terms related to epigenetic. Indeed, it indicated the 
histone modification, MOZ/MORF histone acetyltransferase complex (GO:0070776, 
FDR q-value=6.20E-03) and H3 histone acetyltransferase complex (GO:0070775, FDR 

























5.3 Abnormal Involuntary Movements (AIMs) animal model 
 
The availability of an animal model plays a pivotal role in the study of many neurological 
disorders by granting access to the brain tissues involved in the pathology. In this PhD 
project, we used an animal model of abnormal involuntary movements (AIMs) to study 
both transcriptome and methylome data.  
One of the most difficult challenges in interpreting data from this animal model is to 
distinguish the effect of 6-OHDA injection, the effect of L-DOPA administration, the 
effect of Riluzole treatment, and the changes that might occur simply as biological noise. 
In order to solve these questions, we decided to investigate 3 experimental groups (Table 
11): 
 
1. Group 1 - Rats belonging to this group were unilaterally injected with 6-OHDA 
in the left hemisphere followed by L-DOPA administration, which triggers the tic-
like phenotype. This group represents the main phenotype of interest to investigate 
the effect of L-DOPA administration on hypersensitive striatum.  
Indeed, the 6-OHDA starts to accumulate in the dopaminergic neurons and it 
eventually leads to the production of reactive oxygen species and to cell death. 
The absence of dopaminergic inputs results in dopamine hypersensitivity. The 
subsequent oral administration of L-DOPA, a precursor of dopamine, triggers the 
appearance of abnormal involuntary movements (AIMs). 
2. Group 2 - Rats belonging to this group were unilaterally injected with 6-OHDA 
in the left hemisphere and did not receive any type of additional treatment. This 
group is to be used for identifying those changes that are due to the lesion but not 
to levodopa administration. 
3. Group 3 - Rats belonging to this group were unilaterally injected with 6-OHDA 
in the left hemisphere followed by L-DOPA administration as well as 
administration of Riluzole, a drug used on TS patients. The behavioral tests 
showed a reduction of tic-like symptoms. This group has been used to investigate 






Table 11: Experimental Groups 
Group 1 6-OHDA injection L-DOPA treatment X 
Group 2 6-OHDA injection X X 




It is possible to make several types of comparisons to detect what changes are due to the 
different type of substance injected or administered to the animals. 
For example:  
 
It is possible to start by looking at each group (1-2-3) and comparing the lesioned side 
(L) vs. the contralateral side (C):  
 
(1) 6-OHDA vs. no 6-OHDA (Lesion 2 vs Control 2) 
--> effect of the lesion in untreated animals 
(2) 6-OHDA + L-DOPA vs. L-DOPA but no 6-OHDA (Lesion 1 vs Control 1) 
--> effect of the lesion in L-DOPA-treated animals 
(3) 6-OHDA + L-DOPA + Riluzole vs. L-DOPA + Riluzole but no 6-OHDA (Lesion 3 
vs Control 3) 
--> effect of the lesion in L-DOPA + Riluzole-treated animals  
 
It is possible to compare the contralateral side of different groups: 
 
(4) L-DOPA but no 6-OHDA vs. no L-DOPA and no 6-OHDA (Control 1 vs Control 2) 
--> effect of L-DOPA in not-lesioned animals 
(5) L-DOPA + Riluzole but no 6-OHDA vs. no L-DOPA, no Riluzole, no 6-OHDA 
(Control 3 vs Control 2) 
--> effect of L-DOPA + Riluzole in not-lesioned animals  
(6) L-DOPA + Riluzole but no 6-OHDA vs. L-DOPA but no Riluzole, no 6-OHDA 




--> effect of Riluzole in L-DOPA-treated, not-lesioned animals 
 
It is possible to compare the lesioned side of different groups: 
 
(7) 6-OHDA + L-DOPA vs. 6-OHDA (Lesion 1 vs Lesion 2) 
--> effect of L-DOPA in lesioned animals 
(8) 6-OHDA + L-DOPA + Riluzole vs. 6-OHDA (Lesion 3 vs Lesion 2) 
--> effect of L-DOPA + Riluzole in lesioned animals 
(9) 6-OHDA + L-DOPA + Riluzole vs. 6-OHDA + L-DOPA (Lesion 3 vs Lesion 1) 
 --> effect of Riluzole in L-DOPA-treated, lesioned animals  
 
In the first step of the data analysis we looked at all these type comparisons starting with 
the most obvious ones focused on identifying differences between the lesioned and the 
contralateral side of each group. Subsequently, we performed all the other analyses. 
In the transcriptome project, after looking at all these data, we decided to focus only on 
the effect of L-DOPA and L-DOPA + Riluzole on gene expression changes.  
In the DNA methylation study, we performed a more detailed investigation by looking 
at almost all comparisons to pick out the effect on DNA methylation caused by 6-OHDA 




5.3.1 Striatal DA Determination 
 
In order to check the actual presence of dopaminergic denervation as consequence of the 
unilateral 6-OHDA injection, our collaborator performed an electrochemical detection 
technique coupled with high-performance liquid chromatography (HPLC-ECD) to assess 
the dopamine (DA) levels in the ipsilateral (lesioned) and contralateral (control) striatum. 
As shown in Figure 7, the 6-OHDA lesion results in a drastic decrease (76%) of DA level 
in the striatum. 
 
Fig. 7 from  [151] 
The figure shows the effect of 6-OHDA lesion on the levels of doamine in the striatum.  
**** p < 0.001 
 
5.3.2 The Triggering of the Phenotype by L-DOPA and Riluzole 
 
The manifestation of locomotor activity as a consequence of the treatment in the rodents 
can be seen in Figure 8. The chronic administration of L-DOPA led to the appearance of 
strong abnormal involuntary movements (p < 0.001) while the rodent administered with 
saline only did not show any unusual motor phenotype. Interestingly, the treatment with 
Riluzole was able to reduce the intensity of AIMs triggered by L-DOPA administration 







Fig. 8 from [151] 
The figure shows the phenotypic observation of the abnormal involuntary movements 
(AIMs) in our experimental groups.  Data is shown as mean ± S.E.M. Significant 
differences between the saline and L-DOPA-treated groups are indicated as **p < 0.01 
and ****p < 0.001 and between the L-DOPA and L-DOPA + Riluzole-treated groups 
as ####p < 0.001 
 
5.3.3 Analysis of the Transcriptome 
 
5.3.3.1 Differentially expressed genes: the mRNA is talking 
 
To identify differentially expressed genes, we fed the RNA data into Ingenuity Pathway 
Analysis (IPA) bioinformatics tool. Based on the behavioral data (Fig. 8), we decided to 
study only the effect of Riluzole on gene expression changes and to focus only at the 
following comparisons: L-DOPA vs. Saline and L-DOPA + Riluzole vs. L-DOPA.  
In the first comparison, L-DOPA vs. Saline, we wanted to check the effect of L-DOPA 
administration on gene expression and we were able to identify 667 unique genes. On the 
other hand, by looking at L-DOPA + Riluzole vs. L-DOPA we wanted to identify the 
effect of Riluzole on gene expression and we were able to identify 1200 unique genes 




in both comparisons. The hypergeometric distribution test revealed that the overlap of 
these genes was not random (p = 1.01E-142).  
It was surprising to see how all these 465 genes were differentially expressed in the 
opposite direction: the genes upregulated by chronic L-DOPA treatment were 
downregulated by Riluzole co-administration and vice versa. 
 
Fig. 9 from [151] 
The venn diagram shows the number of significantly differentially expressed genes 
identified in the two comparisons of interest (FDR corrected p-value < 0.01). 
 
5.3.3.2 Identification of the Top Upstream Regulators 
In the L-DOPA vs. Saline analysis (Fig. 9) we identified 667 unique genes that had 
cAMP-responsive element binding protein 1 (CREB1) as top upstream regulator (CREB1 
activation). In L-DOPA + Riluzole vs. L-DOPA analysis we were able to detect 1200 
unique genes and, interestingly, they also had CREB1 as top upstream regulator (CREB1 
inactivation). Moreover, when looking at the overlapping genes (n = 465) CREB1 came 
out on top as the upstream regulator. It appears evident that CREB1 might play a pivotal 
role in the regulation of locomotor movements. The top 10 upstream regulators of the 





Table 12: The top 10 upstream regulators identified in the groups analyzed in our study 







L-DOPA vs. Saline 
CREB1 transcription regulator  7.52 8.53E-31 102 
Forskolin chemical toxicant  6.06 5.56E-23 100 
Cocaine chemical drug  5.58 1.02E-19 48 
PDGF BB Complex  5.22 1.74E-19 61 
beta-estradiol chemical - endogenous 
mammalian 
 4.05 2.01E-19 178 
U0126 chemical - kinase inhibitor -5.07 7.54E-19 76 
CREM transcription regulator  4.19 7.25E-18 39 
dalfampridine chemical drug  4.58 2.66E-17 21 
TGFB1 growth factor  3.82 1.10E-16 166 
bicuculline chemical - endogenous non-
mammalian 
 4.48 7.07E-15 21 
L-DOPA + Riluzole vs. L-DOPA 
CREB1 transcription regulator -6.53 1.21E-11 87 
F2 Peptidase -6.33 8.46E-09 48 
TP53 transcription regulator -2.80 2.41E-08 167 




chemical - other  3.20 3.57E-08 31 
PDGF BB Complex -5.31 6.20E-08 52 
Forskolin chemical toxicant -5.48 1.26E-07 87 
HIF1A transcription regulator -4.27 2.98E-07 58 
CD40LG Cytokine -2.50 3.17E-07 57 
U0126 chemical - kinase inhibitor  4.82 4.30E-07 67 




CREB1 transcription regulator -6.19 1.17E-24 58 
Forskolin chemical toxicant -5.88 5.08E-22 60 
Cocaine chemical drug -4.32 1.71E-15 28 
CREM transcription regulator -3.00 5.60E-15 24 
dalfampridine chemical drug -3.74 2.92E-14 14 
PDGF BB Complex -4.98 3.68E-14 33 
U0126 chemical - kinase inhibitor  4.57 4.27E-13 39 
kainic acid chemical toxicant -4.33 7.23E-13 22 
bicuculline chemical - endogenous non-
mammalian 
-3.65 8.91E-13 14 
IL1B Cytokine -3.60 1.59E-12 54 
Table 12 from  [151] 
The table describe the top 10 upstream regulator of the comparison L-DOPA vs. Saline, 
the comparison L-DOPA + Riluzole vs. L-DOPA and the overlap between the two 
groups. 
5.3.3.3 CREB1 target genes 
Based on all the upstream regulator results, we decided to focus only on CREB1. CREB1 
encodes for a transcription factor that modulates the expression of many target genes 
involved in neuronal processes such as neuronal survival, differentiation and 
development. The RNA data revealed that CREB1 targets genes identified in the 
transcriptome analysis are regulated in the opposite direction by L-DOPA and Riluzole 
(Table 13). 
Table 13: The fold change of CREB1 target genes 
Gene Gene name 
L1vsL
2 L3vsL1 
SRXN1 sulfiredoxin 1 6.08 -3.28 
SLC32A1 solute carrier family 32 member 1 1.79 -1.52 
Sik1 salt inducible kinase 1 3.10 -2.08 
SERTAD1 SERTA domain containing 1 2.83 -1.74 




RHEB Ras homolog enriched in brain 1.49 -1.18 
REM2 RRAD and GEM like GTPase 2 5.42 -2.82 
Pvr poliovirus receptor 2.84 -2.34 
PTGS2 prostaglandin-endoperoxide synthase 2 5.15 -3.08 
PER1 period circadian clock 1 2.18 -1.87 
PDYN Prodynorphin 2.50 -1.75 
PDXK pyridoxal kinase 1.93 -1.69 
NR4A3 nuclear receptor subfamily 4 group A member 3 10.26 -4.16 
NR4A1 nuclear receptor subfamily 4 group A member 1 4.27 -2.15 
NPTX2 neuronal pentraxin 2 4.96 -2.70 
NPAS4 neuronal PAS domain protein 4 5.50 -5.07 
NFIL3 nuclear factor, interleukin 3 regulated 2.08 -1.51 
MIDN Midnolin 2.52 -2.34 
JUNB 
JunB proto-oncogene, AP-1 transcription factor 
subunit 7.83 -3.28 
IRS2 insulin receptor substrate 2 6.01 -3.00 
INHBA inhibin beta A subunit 5.76 -3.41 
IGSF9B immunoglobulin superfamily member 9B 1.93 -1.63 
GPR3 G protein-coupled receptor 3 8.19 -3.95 
GADD45G growth arrest and DNA damage inducible gamma 4.59 -2.92 
GADD45B growth arrest and DNA damage inducible beta 3.43 -1.76 
GAA glucosidase alpha, acid 1.46 -1.34 
FRMD6 FERM domain containing 6 2.16 -1.59 
FOSB 
FosB proto-oncogene, AP-1 transcription factor 
subunit 17.17 -4.96 
FOS 
Fos proto-oncogene, AP-1 transcription factor 
subunit 12.99 -4.94 
FGF13 fibroblast growth factor 13 -1.29 1.26 
EHD4 EH domain containing 4 1.30 -1.30 
EGR4 early growth response 4 10.01 -4.16 




CSRNP1 cysteine and serine rich nuclear protein 1 3.06 -1.88 
CDKN1A cyclin dependent kinase inhibitor 1A 4.09 -2.57 
BAG3 BCL2 associated athanogene 3 1.80 -1.73 
ATF3 activating transcription factor 3 10.98 -6.06 
ARC activity regulated cytoskeleton associated protein 6.41 -2.99 
CREM cAMP responsive element modulator 1.73 -1.52 
JUN 
Jun proto-oncogene, AP-1 transcription factor 
subunit 2.45 -1.70 
PIM3 Pim-3 proto-oncogene, serine/threonine kinase 1.41 -1.39 
VEGFA vascular endothelial growth factor A 1.33 -1.30 
TAC1 tachykinin precursor 1 2.82 -1.92 
STAT3 signal transducer and activator of transcription 3 1.13 -1.13 
SH3KBP1 SH3 domain containing kinase binding protein 1 -1.15 1.13 
PLAT plasminogen activator, tissue type 1.47 -1.48 
NPY neuropeptide Y 1.72 -2.23 
KLF4 Kruppel like factor 4 2.00 -1.60 
HSPA5 heat shock protein family A (Hsp70) member 5 1.64 -1.41 
CRH corticotropin releasing hormone 6.32 -4.62 
CDK19 cyclin dependent kinase 19 -1.22 1.18 
SEMA7A semaphorin 7A (John Milton Hagen blood group) 1.30 -1.27 
Nrgn Neurogranin 1.56 -1.36 
LMO1 LIM domain only 1 1.25 -1.23 
CCND3 cyclin D3 1.22 -1.31 
CDC37 cell division cycle 37 1.27 -1.28 
ID1 inhibitor of DNA binding 1, HLH protein 1.44 -1.57 
NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1 1.19 -1.21 
Table 13 from [151] 
The table reports the fold change of the CREB1 target genes differentially expressed in 
L-DOPA vs. Saline (L1vsL2) and L-DOPA + Riluzole vs. L-DOPA (L3vsL1) (FDR-






5.3.3.4 Revealing the molecular mechanism of Riluzole  
 
To build a molecular mechanism of action of Riluzole, we looked only at CREB1 as the 
top upstream regulator of the differentially expressed genes. We performed literature 
research to look to the functions and all the possible interactions of the proteins encoded 
by CREB1 target genes (Table 13). First, we used UniProt [154] to check the function 
and localization of the genes and their encoded proteins. Subsequently, we used PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) to search for all the experimentally validated 
interactions between the proteins as well as their involvement in L-DOPA, Riluzole or 
Parkinson’s Disorder (PD). Lastly, we built a molecular landscape depicting all those 
protein interactions (Fig. 10). 
The extensive description of all the protein interactions happening in the striatal neuron 






Fig. 10 from [151] The molecular landscape is located in a neuron and shows the functional interactions between proteins encoded by 43 of 




The molecular landscape is gathered around CREB1 localized in the striatal neuron. As 
key signaling 'hub' in the landscape, CREB1 is a pivotal transcription factor that 
modulates the expression of many genes implicated in neuronal activities such as 
neuronal survival, development and differentiation. The literature data have revealed that, 
at least in striatal neurons, CREB1 transcriptional function is activated by L-DOPA [155, 
156]. Moreover, CREM (a component of the CREB transcription factor family) connects 
to CREB1 and regulates its expression. The complex composed of CREB1-CREM 
connects also with FOS and JUN [157]. FOS and JUN connect to each other as well as 
with FOSB and JUNB. FOS, JUN, FOSB and JUNB are part of the transcriptional factor 
complex called AP-1 which engages with CREB1 [158-162] and is known to regulate the 
apoptotic process in response to stress as well as DNA damaging agents [163]. 
Furthermore, JUN transcriptional activity is inhibited by both CREB1 and CREM [157]. 
Also, FOS and JUN connect with ATF3 [164] and CREM engages with the transcription 
factor NFIL3 [165] (see below). JUN modulates the differentiation of neurons and the 
survival of cells. In particular, JUN is able to defend neuronal cells (PC12 cells) from the 
apoptotic process [166]. Interestingly, higher expression levels of FOS were detected in 
rodents that underwent 6-OHDA injection [167, 168] followed by L-DOPA 
administration [169-171].The treatment with L-DOPA results in a higher expression level 
of Fosb but not Junb [172]. In line with these evidences, Junb was found to be a 
protective agent against nigral neurons cell death [173]. 
Additionally, the extracellular signal-regulated kinases 1 and 2 (ERK1/2) - which can be 
located in the cytoplasm and the nucleus – switch on CREB1 and CREM (not shown) 
[174, 175]. Not to mention, ERK1/2 are implicated in higher FOSB expression [176] and 
switch on FOS [177, 178] as well as ATF3 [179]. ERK1/2 were classified as kinases 
modulating the survival of neurons but it has been shown that ERK1/2 also regulate the 
secondary damage mechanisms involved in many neurodegenerative disorders, stroke, 
injury and autoimmune diseases of the CNS [180-185]. Furthermore, several studies 
showed that L-DOPA administration activates ERK1/2 [139, 186-188]. ATF3 and 
ERK1/2 negatively modulate the expression of the anti-apoptotic transcription factor ID1 
[189-191], which in turn decreases the expression of ERK1/2 [192]. The expression of 
ATF3 is usually very low in both neurons and glia cells but rises in response to injury or 




our findings, a chromatin immunoprecipitation study revealed that acute L-DOPA 
treatment in 6-OHDA-lesioned mice increase the expression of Atf3 as well as the 
transcription factors Klf4 and Npas4 transcription factors (see below) [194]. 
 Moreover, NR4A1 and NR4A3 are part of the NR4A orphan nuclear receptor 
transcription factor family which is upregulated under stressful stimuli in the CNS. This 
family of transcription factors (NR4A) is pivotal in the survival of neurons downstream 
of CREB (1) signaling and they might represent a good drug target in neurodegenerative 
disorders [195].  
In the MPTP mouse model of PD, the activation of Nr4a1 results in the preservation of 
dopaminergic neurons [196]. Additionally, Nr4a1 knockout mice show increased 
locomotor activity, higher sensitivity to dopamine [197] and stronger rotational behavior 
induced by L-DOPA [198]. Furthermore, the administration of L-DOPA in MPTP 
monkeys (a non-human primate model of PD) results in increased expression of Nr4a1 is 
increased in the upon L-DOPA treatment in MPTP monkeys [199]. Not to mention, 
analyses on blood on PD patients detected reduced Nr4a1 expression [200]. All these 
findings corroborate our results revealing NR4A1 overexpression. In the molecular 
landscape, NR4A1 connects with NR4A3 resulting in a functional complex [201], 
NR4A1 reduces FOSB activity [202] while SIK1 kinase is upregulated by CREM [203] 
– reduces the expression of NR4A1 [204]. On top of that, NR4A1 is activated by TAC1 
[205], an extracellular anti-apoptotic protein with extracellular localization [206] highly 
expressed in a primate model of L-DOPA induced dyskinesia [207]. TAC1 also increases 
the expression of FOSB [208], which can also be located in the cytoplasm where it 
constitutes a molecular complex with BAG3, a co-chaperone protein involved in the 
regulation of neuronal apoptosis and autophagy [209, 210]. Noteworthy, the autophagy 
modulated by Bag3 is implicated in the clearance of aggregated proteins often linked to 
neurodegenerative disorders [211-213]. To conclude, the expression of JUNB [214] is 
upregulated by the corticotropin-releasing hormone (CRH), a central nervous system 
(CNS) neurotransmitter [215] involved in the regulation of neuronal apoptosis [216] as 
well as the activity of dopaminergic neurons [217]. The expression of CRH is increased 
by FOSB [218]. The expression of NR4A1 [219], TAC1 [220] and the growth factor 
VEGFA (see below)  [221] is positively regulated by CRH which switches also on 




 Another major cascade depicted in the molecular landscape originates from 
CDKN1A, a transcription factor implicated in the death of dopaminergic cells as 
consequence of 6-OHDA injection [224]. CDKN1A turns off both FOS and JUN [225] 
while it switches on ERK1/2 [226]. The expression of CDKN1A is increased by KLF4 
and ERK1/2 [227] and the expression of KLF4 is upregulated by ERK1/2 [228]. In 
addition, the expression of CDKN1A is increased by the growth factor FGF13 (see 
below), the transcription factor SERTAD1 and the cytoplasmic protein FRMD6 [229-
231] whereas the expression of CDKN1A is reduced by ID1 and BAG3 [232, 233]. 
CDKN1A turns also off CCND3 [234], a cell cycle regulator which is highly expressed 
during the apoptosis of dopaminergic neurons induced by 6-OHDA injection. It is a very 
interesting evidence considering that a dysregulation of cell cycle has been proposed as 
one of the causes leading to the death of dopaminergic neurons in Parkinson's disease 
(PD) [235]. In addition, GADD45G – a member of the GADD45 family whit pivotal role 
in the regulation of apoptosis [236] – connects and engages with CDKN1A thus leading 
to its increased expression [237]. GADD45G connects and engages also with MIDN 
[238], a gene strongly linked to PD [239, 240]. GADD45G, GADD45A and GADD45B 
– which also positively regulates the expression of CDKN1A [241] – connects with each 
other to generate a molecular complex [242]. Noteworthy, the knockout of Gadd45b in 
L-DOPA-induced dyskinesia (LID)-rodent model leads to higher expression of FOS and 
FOSB [243], which hints that Fos and Fosb expression is downregulated by GADD45B 
(not shown). A second study on LID rodent model reported the treatment with L-DOPA 
increased Gadd45b and Gadd45g expression in the lesioned side of the striatum [244]. 
Gadd45a is also implicated in 6-OHDA-induced brain toxicity [245]. At last, Gadd45b 
expression is downregulated by NFIL3 [246], a transcription factor with neuronal 
neuroprotective function [247]. 
 Several of the proteins depicted in the molecular landscape engage with STAT3, 
a protein that promotes the proliferation of neuron to contrast the cell death induced by 
6-OHDA injection [248]. In the nucleus, STAT3 is turned off by GADD45A [249], 
KLF4 [249] and CDKN1A [250]. On the other hand, STAT3 turns on CDKN1A [251] 
and negatively modulates GADD45B and GADD45G expression [252, 253]. In the 
cytoplasm, STAT3 engages with HSPA5 to originate a molecular complex. As shown in 




to mention, a rodent model of PD has shown that high levels of Hspa5 are able to defend 
dopaminergic neurons from degeneration [256]. HSPA5 expression is upregulated by 
ERK1/2 [257]. In turn, BAG3 negatively modulates ERK1/2 activity [258]. To 
complicate things, STAT3 and ERK1/2 positively regulate each other [259, 260]. 
Furthermore, the expression of VEGFA is upregulated by STAT3 (see below) which is 
activated by the extracellular neuroendocrine protein secretogranin-2 (SCG2) [259]. 
SCG2 encodes for a protein called secretoneurin (SN) (not shown) which is involved in 
differentiation of neurons [261] and is also able to increase the expression of anti-
apoptotic proteins via STAT3-dependent cascade [259]. The expression of SCG2 is 
regulated by ERK1/2 [262] while FOS-JUN modulate the activity of SCG2 [261]. FOS-
JUN are also involved in the positive modulation of SRXN1 [263], a cytoplasmic enzyme 
with a protective role in the deterioration of dopaminergic neurons observed during 
oxidative stress [264, 265]. 
 In the molecular landscape, many signaling cascades have ERK1/2 as main actor. 
To start with, ERK1/2 is activated by TAC1 (see above) [266], while the expression of 
TAC1 [267] and PTGS2 [268] is upregulated by ERK1/2. The regulation of the 
cytoplasmic enzymes encoded by PTGS2 is controlled positively by CRH [269] and 
VEGFA [270] (see above) and negatively by NFIL3 (see above) [271]. Further, the 
activity of NPTX2 is regulated by ERK1/2 [133, 272], while NPAS4 upregulates the 
expression of NPTX2 expression [273]. NPTX2 plays a role in the development of 
neurons, the formation of synapses, and the growth of neurites [274, 275]. Moreover, one 
study on PD patients observed, in the substantia nigra, a really high upregulation (>800%) 
of Nptx2 [275] while another study showed that L-DOPA treatment increases the 
expression of Nptx2 and the severity of locomotor activity decreases in Nptx2 knockout 
mice [133]. In addition to this complicated cascade, the SH3KBP1 and IRS2 regulate the 
activity of ERK1/2 activity [276]. IRS2 encodes for cytoplasmic protein, usually 
involved in the apoptotic process, positively modulated by ERK1/2 [277]. Worth to 
mention, the injection of 6-OHDA results into Irs2 degradation [278]. Moreover, the 
expression of IRS is decreased by the GTP-binding protein RHEB [279] which is also 
able to turn off ERK1/2 [280]. RHEB encodes for a gene that is involved in the regulation 
of neuronal plasticity and differentiation. One study in an animal model of PD reported 




Interestingly, if overexpressed, Rheb’s function switches and it results in the activation 
of the apoptosis process. The expression of EGR4 is also upregulated by ERK1/2. EGR4 
encodes for a transcription factor that is increased as consequence of L-DOPA 
administration [133]. A negative regulator of ERK1/2 is represented by DUSP14 [284, 
285]. Striatal neurons lacking dopamine in LID model showed downregulation of the 
ERK signaling [138, 286]. DUSP14 is also responsible for the reduced expression of the 
extracellular enzyme PLAT [287] which is involved in migration and plasticity of 
neurons [288]. The pro-survival/anti-apoptotic role of Plat has been shown by in-vitro 
and ex-vivo studies [289]. The expression INHBA is increased by PLAT [290] while the 
activation of ERK1/2 is regulated by PLAT and INHBA [291, 292]. 
Moreover, INHBA positively modulates JUNB [293] and VEGFA expression 
[292]. In turn, the activation of JUNB [294] and ERK1/2 [295] is modulated by the 
growth factor VEGFA which is positively regulated by the growth factor FGF13 [296]. 
FGF13 modulates the activity of JUNB [158]. The administration of VEGFA to 6-
OHDA-lesioned rats results into a significant boost of neurons [297]. To continue, the 
expression of FOSB and NR4A3 is increased by VEGFA [298, 299] (see above) while 
the expression of PLAT is increased by VEGFA, TAC1 and KLF4 [300-302]. PLAT is 
also activated by CRH [303] while the activation of CRH is regulated by NPY, an 
extracellular hormone redundant in the CNS where it modulates the apoptotic process in 
a negative way and it controls the autophagic process in a positive way [304, 305]. The 
activation of ERK1/2 is regulated also NPY [306]. A study on PD patients showed 
increased striatal expression of the neuroprotective agent NPY [307]. Further, SIK1 
downregulates the expression of CRH [308] (see above). The expression of ARC is 
upregulated by SIK1. ARC encodes for a brain-specific protein involved in the apoptotic 
process [309] that was found upregulated in LID striatal neurons [310, 311]. Further, the 
activation of ARC is modulated ERK1/2 [312] while PDYN turns off ARC [313]. PDYN 
encodes for a neuropeptide with anti-apoptotic function [314]. The expression of Pdyn is 
upregulated by TAC1 [208]. Once again, LID animal model studies detected increased 
striatal PDYN expression [315-317]. To conclude, the expression of PER1 is upregulated 
by ERK1/2 [318] and FGF13 [319] while it is blocked by NFIL3 [154] (not shown). The 





5.3.3.5 Validation of the mRNA data 
  
In order to validate the RNA sequencing data, we performed a qPCR on 10 CREB1 target 
genes. As shown in Fig. 11, we were able to validate 8 out of 10 genes therefore we 
assumed that the RNA sequencing data used in this project reflect real expression 
changes. 
 
Fig. 11 from [151] 
The figure shows the qPCR values [log2FC (Mean + SEM)] of the genes selected for the 
validation of mRNA data, blue represents L-DOPA vs. Saline while green represents 




5.3.4 DNA methylation profile in the striatum of our AIMs model 
 
In order to study the methylation pattern in the striatum of rodents showing abnormal 
involuntary movement we decided to perform genome wide methylation studies (RRBS). 
As shown in Table 11, we had 3 experimental groups that underwent different treatment. 
To extrapolate the effect of each treatment on methylation levels, we firstly compared 
samples within the same group (lesion and contralateral side) and later on between 
different groups using a similar approach: 
 
1st step -> comparison of the two datasets to identify the common CpGs 
2nd step -> observation of the genomic distribution of the identified CpGs  
3rd step -> identification of differentially methylated sites (DMSs)  
4th step -> annotation and gene enrichment analysis 
 
5.3.4.1 Distribution of CpGs in the rat genome 
 
In case of the DNA methylation experiment (n = 3), we did not have the same statistical 
power as for the RNA sequencing (n = 8), therefore we took a different approach and 
started by comparing the lesion to the control side. In each group analyzed (3 animals, 
control and lesioned sides) the RRBS protocol was able to detect approximately 435,000 
CpGs. The majority of CpGs (>50%) was located in intergenic regions (Fig. 12). In 
promoters and introns, we detected approximately an equal amount (~20% each). The 
remaining CpGs were located in exons (less than 10%). The distribution of CpGs in the 
rat genome was similar for all groups investigated in this study (Group 1, Group 2 and 





Fig. 12: The figure shows the distribution of CpGs (%) in the rat genome.  
 
We also looked at the distribution of CpGs in the area of the genome enriched in cytosines 
(Fig. 13). The most CpG dense regions are called CpG islands (CGI), while area of the 
genome with intermediate CpG density, located within 2kb of CpG islands, are called 
CpG shores. The majority of the CpGs (>60%) were located outside islands and shores. 
In CpG islands, we found more than 20% of the targeted CpGs while the remaining CpGs 
are located in shores (10%). The distributions of cytosines identified and analyzed was 
similar for all groups investigated in this study.  
 
 








































5.3.4.2 Identification and localization of the methylated sites 
 
To identify the effect of 6-OHDA injection alone or in combination with either L-DOPA 
administration or the impact of Riluzole treatment, we looked at each individual group 
and compared the methylation levels of control sides to the methylation levels of the 
lesioned side to identify the presence of differentially methylated sites (DMSs). DMSs 
were designated as CpG dinucleotides with statistically significant methylation level 
differences after correction for multiple testing (q < 0.01). Table 14 shows the total 
number of striatal DMSs. The highest number of DMSs (54) were detected in the lesion 
only group (G2) and distributed almost equally (25, 29) in decreased (hypo) and increased 
(hyper) methylation levels. In the case of the L-DOPA treated group (G1) we detected 
only 14 DMSs, all of them undergoing loss of methylation, while the administration of 
both L-DOPA and Riluzole treatment (G3) resulted in very few DMSs.  
 
Table 14: Number of DMSs detected in each group when comparing the lesion to the 
contralateral side of striatum 
 Hyper Hypo Total 
G1 0 14 14 
G2 25 29 54 
G3 4 1 5 
 
All together these numbers indicate that less than 0.02% of all investigated CpGs 
underwent statistically significant DNA methylation changes. These findings show that 
methylation levels in the lesioned and the contralateral striatum are very similar 
regardless the type of treatment administered.  
 
The behavioral data (Fig. 8) showed that 6-OHDA injection alone has no effect on the 
locomotor activity of the animals, while the methylation data revealed almost no changes. 
As next step, we decided to compare the DNA methylation levels between different 
groups. We first compared the control side (n = 3) of the L-DOPA treated group (G1) 
with the control side of the animals undergoing no treatment (G2). As indicated in the 




compared the lesioned side. Interestingly, when we looked at the control side of the L-
DOPA + Riluzole treated animals (G3 group) and the control only animals (G2) we 
identified even more DMS, the majority undergoing hypomethylation (Table 15). 
Surprisingly, when we looked at the L-DOPA (G1) and the L-DOPA + Riluzole (G3) 
comparison, we detected very few DMSs (only slightly superior in the number of the 
comparisons described in the Table 14). 
 
Table 15: Number of DMSs identified when comparing different groups 
 Hypo Hyper Total 
G1 vs. G2 
Control side 
867 258 1125 
G1 vs. G2 
Lesion side 
687 253 940 
G1 vs. G3 
Control side 
54 64 118 
G1 vs. G3 
Lesion side 
46 67 113 
G3 vs. G2 
Control side 
1260 256 1516 
G3 vs. G2 
Lesion side 
1143 289 1432 
 
By looking at the lesioned and control side it is impossible to observe any significant 
differences in the number of hypomethylated and hypermethylated DMSs. Altogether 
these data further confirm that the lesioned and contralateral side of the striatum have 
almost identical methylation profiles. Furthermore, they also strengthen our hypothesis 
that 6-OHDA treatment induces only very few DNA methylation changes while the 








5.3.4.3 A new way of analysis: merging the lesion and contralateral side  
 
Based on the high similarity of the methylation levels observed so far, we decided to 
merge the 3 lesioned and the 3 control sides of each group to obtain a new group made 
up of the 6 striata in order to increase the statistical power. Moreover, we also relaxed the 
bioinformatic analysis criteria: the detection of a CpG in at least 4 out of the 6 striata was 
mandatory for any CpG to be included in the analysis. By doing so, we could substantially 
increase the number of analyzed CpGs (~600,000) without altering the genome-wide 
distributions of this background. 
Subsequently, we looked at the presence of DMSs, and we observed a global increased 
number of significantly methylated sites compared to the previous analysis where 
lesioned and control sides were separately compared (Table 16). The overall higher 
number of hypomethylated CpGs of the L-DOPA treated animals was still prevalent. 
Indeed, the comparison G1 vs. G2 picked-up 1243 hypomethylated sites while the 
comparison G3 vs. G2 detected 2106 hypomethylated sites. Moreover, the comparison 
G1 vs. G3 (Table 16) detected very few DMSs (297) without a clear tendency for either 
hypo- or hypermethylation. Based on these results we decided to focus our attention only 
on the G1 vs. G2 and G3 vs. G2 comparisons. 
 
Table 16: Number of DMSs after merging the lesion and the contralateral side in a 
single group 
 Hypo hyper Total 
G1 vs. G2 1243 510 1753 
G1 vs. G3 179 118 297 
G3 vs. G2 2106 530 2636 
 
The genomic distribution of the DMSs (Fig. 14) revealed that most of the significantly 
methylated sites are located in intergenic regions (~60%) or intronic area (~25%) while a 






Fig.14: The figure shows the distribution of DMSs (%) in the rat genome.  
 
The distribution of DMSs in CG rich area showed that the majority of DMSs detected by 
the analysis are located outside CpG islands or shores (85%) (Fig. 15). Once again, we 





Fig.15: The figure shows the distribution of DMSs (%) in CG enriched area.  
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5.3.4.4 Genes with marked changes in methylation 
 
To further analyze G1 vs. G2 and G3 vs. G2, we looked at the density of DMSs to check 
if the similarities observed so far were systemic. To check the density, we built 
“segments” of 1Mb and counted the number of DMSs detected in each segment for both 
comparisons. 
The subtraction of these segments (X segment (G1 vs. G2) – Y segment (G3 vs. G2)) 
revealed which were the segments with the biggest difference in number of DMSs. The 
density analysis revealed that there are some genomic regions which differ a lot between 
the two comparisons. Moreover, the combined treatment of L-DOPA and Riluzole 
resulted in the identification of some interesting segment. For example, the region nearby 
the phosphatidylinositol glycan anchor biosynthesis class X (PIGX) gene, had 9 DMSs in 
L-DOPA + Riluzole treatment but none in L-DOPA only administration. The 
physiological function of this gene is involved in the biosynthesis of glycolipids. 
Similarly, the region nearby the COMM domain containing protein 1 (COMMD1) does 
show 6 DMSs in case of L-DOPA + Riluzole treatment. COMMD1 encodes for a scaffold 
protein involved in the modulation of the aggregation of misfolded protein typically 
observed in PD. However, the data revealed that treatment with L-DOPA only or with L-
DOPA + Riluzole results in a similar methylation profile, with the exception of these few 
genomic areas. Indeed, we observed a clear correlation between the methylation level of 
CpGs in the animals (r = 0.52). This correlation became even higher (r = 0.98) by looking 
at DMSs in treated groups (L-DOPA and L-DOPA + Riluzole) relative to the saline only 
group.  
In the next step, we decided to look at those genes which underwent marked changes in 
DNA methylation levels upon the administration of L-DOPA or L-DOPA + Riluzole 
(Table 18).  
Table 18: Number of DMSs with drastic changes in methylation levels 
 L-DOPA L-DOPA + Riluzole 
=>80% methylation levels 14 22 






We first looked at the changes of at least 80% in either loss or gain of methylation. The 
treatment with L-DOPA resulted in 68 DMSs exhibiting at least 80% loss of methylation 
and 14 DMSs having at least 80% increased of methylation. On the contrary, the L-DOPA 
+ Riluzole treatment resulted in 66 DMSs exhibiting at least 80% loss of methylation and 
22 DMSs having at least 80% increased of methylation. Table 19 shows the genes that 
we were able to annotate using these DMSs. In bold are listed the genes with literature 
reports with terms “L-DOPA” or “Brain”. Once again, we observe many similarities in 
the DMSs detected in the two groups. 
 
Table 19: List of the genes showing drastic changes in methylation levels 
 <=80% methylation levels =>80% methylation levels  
 
L-DOPA AlzDis, Cox6b1, Ctnnbl1  
Dcdc2, Itih4, Kif5a 






L-DOPA + Riluzole  
common genes 
Akna, Dlgap2, Masp1 
Morn4, Myh7b, Nid2 
Padi3, Plcg2, Tgm2 
Ttll1, Zfand3, Zfyve21 
Asic2, Dnai2, Ntng1 
 
L-DOPA + Riluzole Disc1, Fer1l4, Irf2  














5.3.4.5 The biological relevance of the DMSs 
 
To have a clear picture of the biological role of the DMSs picked-up by RRBS, we 
performed a gene enrichment analysis using the GOrilla tool. In these analyses we 
compared any DMSs (either hypo or hyper) located nearby genes to its relative 
background. The background was defined as all the genes in the dataset that had at least 
one DMS detected.  
Interestingly, the G1 vs. G2 comparison identified 549 genes, and the enriched GO terms 
analysis showed many terms directly related to processes like neurodevelopment, 
neurotransmission, glutamate signaling, and neuron remodeling. The G3 vs. G2 
comparison yielded similar results: we identified 830 genes and the GO term analysis 
showed terms related to synapse function, neuron differentiation, epigenetic 

























6.1 Genetic studies of Tourette Syndrome 
 
In the genetic association studies, we wanted to investigate SNPs in the 3’UTR of 
Tourette candidate genes. We decided to focus mostly on genetic variations predicted to 
alter the binding site of miRNAs. Indeed, there is a chance that SNPs in that area might 
have a greater impact on the gene expression due to the downstream effect manifested via 
the regulation mediated by miRNAs.  
The dataset used in the analysis was composed of 148 families and 290 case-control 
samples. Samples were collected by the TSGeneSEE consortium collection and the 
dataset at our disposal was a mix of four different populations (Hungarian, Polish, Italian, 
Greek). In order to properly analyze the dataset, we had to separate the families from the 
case-control samples and check for population stratification. We analyzed the families 
using a TDT test while for the case-control genetic association we used a meta-analysis. 
The need to separate the two analyses resulted in a low-sample size that hindered the 
statistical power of the genetic study.   
The Real-Time PCR experiments did not reveal any positive findings, while the 
OpenArray yielded some interesting results. The meta-analysis (Table 5) showed a 
significant association of rs3750486 (p = 0.021, MCPerm p-value = 0.001) located in the 
LHX6 gene with TS. LHX6 codes for a member of a large protein family expressed in the 
developing and adult mouse basal ganglia [321]. LHX6 is thought to be a regulator of 
neuronal cells differentiation [322]. It is also a component of striatal activity modulation 
which is a brain region clearly linked to TS pathology [323, 324]. From a genetic point 
of view, LHX6 has been already proposed as TS candidate gene [325]. We looked at 
linkage disequilibrium between the SNPs identified by the previous study [325] and the 
SNP detected in our 3’UTR analyses. We saw that they are not related (D’ = 0.293; r2 = 
0.004). It is interesting to speculate, given the 3’UTR location of rs3750486, that we are 
detecting the genetic polymorphism that may alter the gene expression through a 
mechanism regulated by miRNAs. Indeed, rs3750486 of LHX6 is in a putative target 




the presence of the A allele, while the presence of the G allele might create a changed 
sequence possibly suitable for other miRNAs (mir-4447, mir-4472). 
The second suggestive finding of our meta-analysis is rs7795011 (p = 0.029, MCPerm p 
= 0.009) at the IMMP2L gene. IMMP2L encodes for a protein that is involved in the 
disposal of signal peptide sequences needed to direct mitochondrial proteins in the 
mitochondria. There are a number of CNV studies linking IMMP2L to TS [20-23]. In this 
study, we found no genetic variations with a putative connection to miRNA regulation.  
The TDT test analysis revealed a positive TS association with rs1042201 (p = 0.029) in 
the AADAC gene, the same gene picked up in the meta-analysis. AADAC is an enzyme 
involved in lipolysis and metabolism of drugs. It is principally expressed in the liver, the 
adrenal glands and the pancreas [326], therefore there is no clear indication about AADAC 
function in the human brain. A recent CNV genetic study, found positive association in a 
Danish TS cohort and the subsequent meta-analysis done over 1000 TS patients and 
100,000 controls confirmed the role of AADAC deletions in TS pathogenesis [24]. Worth 
to mention, the genetic study was also reporting, at least in mice, the presence of AADAC 
protein in several regions of the human brain (hippocampus, corpus callosum and caudate 
nucleus) previously connected to Tourette Syndrome [327]. In addition, the 3’UTR SNP 
detected in our genetic study, rs1042201 is a putative target of mir-4263 which may play 
a role in human embryonic stem cells and neural forerunners [328]. 
SLITRK1, the most studied gene in Tourette Syndrome, did not yield a positive finding. 
The results of our genetic studies are consistent with many of the literature findings which 
investigated the role of SLITRK1 in the etiology of TS and failed to detect brand-new 
variations as well as to duplicate the known ones [52-57]. It should be noted that the 
power of our study is limited by the small sample size, therefore is not surprising that we 
detected few positive associations. This phenomenon is usually referred to as the missing 
heritability, which states that most of the genetic variance is still elusive due to the small 
effect on the phenotype of interest. To fully uncover those effects, large sample sizes are 
needed. However, we observed a similar trend in the results of the TDT and the meta-
analysis. So, it is possible to assume that our results are robust. 
In conclusion, we identified positive association between rs1042201 in AADAC and 
significant association between rs3750486 in LHX6 and rs7795011 in IMMP2L genes 




of TS. We are speculating that some of those influences may arise from miRNAs 
mediated modulation of gene expression. However, further association studies on larger 
populations as well as functional validation follow-up studies are warranted. 
 
 
6.2 Epigenetic studies of Tourette Syndrome 
 
In this project we wanted to investigate genome wide DNA methylation changes on blood 
samples of patients with a tic phenotype.  
The samples were collected in the Netherlands and we described the first ever genome 
wide methylation analysis (EWAS) on tic disorders. One of the difficulties we first 
encountered was the establishment of an adequate sample size. The dataset was based on 
a self-reported questionnaire where patients would describe the manifestation of tics. The 
use of self-reported questionnaires is quite common. Indeed, in many cases, the medical 
centers responsible for the diagnosis and blood collection might be far from the hometown 
of the patients, therefore it is not possible to personally recruit or examine all the 
participants during the manifestation of tics [329], and clinicians rely on a self-report 
questionnaire to have an general overview of the symptoms.  
The second factor we had to consider during the analysis of the dataset was represented 
by the heterogeneity: we had to correct for several factors like age, smoking, sex, tics, 
cell type and the position on the array. Indeed, it is known that all of these elements, with 
the exception of tics, affect DNA methylation levels [330-332]. 
Once the dataset was cleaned, we performed the EWAS. We did not find any significant 
CpG site after correcting for multiple tests. However, we were able to identify 57 CpGs 
that had an interesting p-value (<0.0001). The gene-ontology analysis and the subsequent 
literature research of the top CpGs, showed that many CpG sites are in proximity to genes 
previously associated with psychiatric or neurological disorders. 
For instance, two CpGs (cg08093277 and cg21879791) are located near the gamma-
aminobutyric acid type B receptor subunit 1 (GABBR1) gene which encodes for a 
component of the major inhibitory neurotransmitter (GABA) in the central nervous 




Moreover, we identified genes linked to Alzheimer’s disease as BLM RecQ like helicase 
(BLM) and ADAM metallopeptidase domain 1A (pseudogne) (ADAM1)  [337, 338] or 
schizophrenia as for clathrin interactor 1 (CLINT1) [339, 340]. More examples are 
SLC25A48 solute carrier family 25 member 48 (SLC25A48) which is a susceptibility 
gene for PD [341] and pleckstrin homology and RhoGEF domain containing (PLEKHG3) 
gene which is linked to mental retardation [342, 343]. Furthermore, some of the 57 CpGs 
point towards brain specific genes. For instance, syntrophin gamma 1 (SNTG1) connected 
to tic phenotype and that is expressed in the central nervous system [344] or Semaphorin-
4G (SEMAG4G) which may be involved in cerebellar development [345].   
Interestingly, two of the 57 CpGs (cg12961733 on BRD1 and cg03573179 on BRPF3) 
lead to the involvement of MOZ/MORF, a histone acetyltransferase structure that 
modulates the dentate gyrus [346]. Acetylation is a post-translational modification that 
counteracts the positive charge of the histone tails amino group, thus resulting in the 
switch from a compacted chromatin structure (repression of transcription) to a more 
relaxed one (transcriptional activation). The MOZ/MORF subunit is made of 
bromodomain PHD finger protein (BRPF1/2/3), inhibitor of growth 5 (ING5) and 
homolog of Esa1-associated factor 6 (hEAE6) [347]. Moreover, bromodomain containing 
1 (BRD1) which is linked to schizophrenia and bipolar disorder [206, 348], and 
bromodomain and PHD finger containing 3 (BRPF3) are components of the histone H3 
acetyltransferase activity within the MOZ/MORF complex [349]. Furthermore, one CpG 
site is located near histone cluster 1 H4 family member e (HIST1H4E) gene, a member 
of histone 4 family which is a subunit of the nucleosome. The nucleosome modulated 
biological processes like transcription and DNA replication by compacting the DNA into 
chromatin. 
The gene ontology analysis and the literature research have shown an involvement of 
epigenetic and neuropsychiatric genes. However, further studies on larger sample size or 
a more defined phenotype are warranted [121]. 
For example, future studies could consider a different approach that would include not 
only tics but also neurodevelopmental disorders that usually appears with TS such as 
OCD, ADHD and autism. Moreover, a longitudinal approach should also be taken into 
consideration to investigate at what stage of the disorders each environmental factor starts 




6.3 Abnormal Involuntary Movements (AIMs) animal model  
In the transcriptome and methylome study of the AIMs animal model we wanted to 
investigate the region directly related to the manifestation of tics: the striatum. 
The use of the animal models represents a very good option to perform molecular and 
biological studies in brain tissues involved in the pathogenesis of neurological disorders. 
Tourette Syndrome has a very complex and heterogeneous phenotype: the tics appears in 
situation of stress, the intensity and the severity of tics is always different, each patient 
manifest unique symptoms. It is impossible to have a single animal model capable of 
resembling all these facets. So, we decided to build the animal model based on the 
pathological situation observed in TS patients, a state of hypersensitivity to dopamine. 
The animal model was established by our collaborators at Boehringer Ingelheim. The 
behavioral data (Fig. 8) showed that administration of L-DOPA to the hypersensitive 
striatum triggers the appearance of so-called tics. It was originally planned as a Tourette 
Syndrome animal model but, after thinking about the biological background, observing 
the phenotype and discussing with experts in the field, we agreed that the model would 
not fit Tourette Syndrome but would fall under a different classification: abnormal 
involuntary movements (AIMs).  
By using brain samples from this AIMs animal model, we wanted to investigate the effect 
of L-DOPA treatment on the locomotor activity as well as the counteracting effect 
mediated by the administration of Riluzole, a glutamatergic compound already implicated 
in the attenuation of AIMs. Indeed, the behavioral data showed that treatment with 
Riluzole reduced the locomotor activity (Fig. 8).   
The transcriptome experiment showed that Riluzole treatment results in changes in the 
mRNA expression of those genes that are linked to the appearance of abnormal locomotor 
activity. The same genes which are highly expressed after the administration of L-DOPA. 
The mRNA data showed that Riluzole is able to counteract the effect mediated by L-
DOPA on gene expression changes. Surprisingly, we observed that CREB1 was the top 
upstream regulator in all the groups investigated. Therefore, we decided to focus only on 
CREB1 target genes in order to build a molecular network that might explain the effect 
of L-DOPA and Riluzole on gene expression (Fig. 10). 
The molecular landscape indicates that the regulation of the apoptotic process has a 




reduction of locomotor activity seen after Riluzole treatment. In general, the CREB1 
target genes lead to the hypothesis that L-DOPA administration leans towards increased 
neuronal survival, while the Riluzole treatment triggers apoptotic processes. Worth to 
mention, many of the genes depicted in the landscape encode for anti-apoptotic proteins. 
The same genes that are upregulated by L-DOPA administration were downregulated by 
the Riluzole treatment. Specifically, as shown by the upstream regulators (Table 10), the 
neuronal reaction to Riluzole is carried out via decreased activity of CREB1. So, CREB1 
acts as a remote controller with “go-between” commands. For instance, the activation of 
CREB1 is modulated by phosphorylation mediated by the kinase ERK1/2 [350] and 
protein kinase C (PKC) [351]. The activation of CREB1 results into the upregulation of 
anti-apoptotic genes and ultimately in less apoptotic process [352]. On top of that, 6-
OHDA-lesioned rats followed by L-DOPA showed a surge in striatal neuron CREB1 
phosphorylation [353, 354]. To conclude, a recent study showed that CREB1 
phosphorylation is reduced by Riluzole [355]. 
The exact mechanism explaining how Riluzole would reduce the activity of CREB1 is 
still unknown. By looking at what is reported in the literature and at the transcriptome 
data, we were able to propose a mechanism (Fig. 17) that might explain this mystery. In 
our opinion, Riluzole reduces the activity of CREB1 leading to a modulation of the 
apoptotic process, and ultimately lower AIMs. To start with, Riluzole has many anti-
glutamatergic properties [356-359] that negatively regulate the glutamatergic 
neurotransmission. The release of glutamate is able to trigger the post-synaptic NMDA 
receptors function, thus leading to the activation ERK1/2. The upregulation of ERK1/2 
leads to CREB1 phosphorylation/activation [350]. To recapitulate, Riluzole would 
decrease the activity of CREB1 by decreasing the ERK1/2 signaling modulated by NMDA 
receptor. To continue, Riluzole is a strong inhibitor of PKC [360], a kinase directly 
involved in the phosphorylation/activation of CREB1 [351]. Moreover, PKC activates 
CREB1 also indirectly by positively modulating the NMDA receptors, thus leaning on 
the effect mediated by active ERK1/2 [361].  
It is important to remember that even though the transcriptome data provided very 
interesting results, further studies to confirm this molecular mechanism are warranted. 
Indeed, we were not able to confirm that Riluzole leads to reduced CREB1 activity by its 




the phosphorylation of CREB1 is a pivotal contributor in the manifestation of AIMs. For 
instance, several drugs such as amphetamines, cocaine, and the anti-psychotic 
aripiprazole (all involved in the appearance of AIMs) [362-364] trigger the activation of 
neuronal CREB1 throughout a mechanism of phosphorylation [365-367]. To conclude, 





Fig. 17 from [151] 
Schematic representation of the molecular mechanism of action of Riluzole via CREB1 
activity. The appearance of AIMs is affected by CREB1 activity and its role in the 
modulation of the apoptotic process. Riluzole blocks the glutamate pathway leading to 
reduced ERK1/2 signaling and diminished CREB1 activity. Riluzole could also block 





In the DNA methylation experiments, we wanted to investigate genome wide DNA 
methylation pattern that might influence the appearance of locomotor activity. It is widely 
known that DNA methylation usually correlates to gene expression: hypomethylation 
leads to gene expression while hypermethylation leads to gene repression. The area 
nearby gene promoters are often enriched in stretches of DNA with high CpG density 
(CpG islands), which play a pivotal role in modulating gene expression changes. 
Considering the role of DNA methylation in transcriptional regulation we thought that 
abnormal methylation patterns would influence the appearance of locomotor activity 
observed after chronic treatment with L-DOPA. Supporting our hypothesis, a recent paper 
has shown how methylation regulates the appearance locomotor activity in a L-DOPA 
induced dyskinesia (LID) animal model [244].  
We used a method called RRBS, which was not fully annotated on the rat genome, thus 
making the bioinformatics analysis more complicated given the absence of basic 
information on rodent methylation patterns. We observed an overall decrease of 
methylation (linked to higher gene expression) and discovered that most of the changes 
were located outside promoters/CpG islands.  
Interestingly, the same genomic distribution observed in our study was also found in a 
paper investigating DNA methylation changed in the L-DOPA induce dyskinesia animal 
model [244]. Functionally speaking, those findings make sense with the pathological 
manifestation of locomotor activity. Indeed, the 6-OHDA injected rodents show a pretty 
normal behavior in absence of L-DOPA treatment which, once administered, leads to 
changes in gene expression and tic manifestation (as shown by the transcriptome data). 
In addition, intergenic areas of the genome are thought to be involved in the modulation 
of transcription levels and alternative splicing therefore it is possible to speculate that 
they might contribute to the abnormal transcriptional expression observed in animal 
model of AIMs/LID [244, 368-371]. Moreover, the extensive transcriptional changes 
observed in the mRNA data is unlikely explained only by changes in promoter region 
which are usually easily accessible by definition.  
The DMSs analyses revealed that treatment (L-DOPA and Riluzole) administration has 
an influence on DNA methylation levels, mostly resulting in hypo-methylation which 
subsequently could lead to gene expression and might result in the manifestation of 




striatum clearly demonstrated that 6-OHDA injection (lesioned side) has no significant 
effects on dynamic methylation changes. In addition, the data clearly showed that those 
changes in DNA methylation happen regardless the type of treatment: L-DOPA or L-
DOPA + Riluzole. However, the comparison between the two different treatments (G1 
vs. G3) did not show that many changes. It is interesting to speculate, based also on 
behavioral and mRNA data, that we are detecting the counteracting effect of Riluzole on 
gene expression which might be reflected also by less overall changes in DNA 
methylation detected when the two treatments were compared. 
We also identified some regions with high density of DMSs and the following analysis 
focused only on high methylation changes (at least 80%) was able to identify few genes 
undergoing drastic variations in DNA methylation levels. It is worth to mention that we 
detected few genes because of the very stringent criteria used in the analysis as well as 
the difficulties in annotating the DMSs to a gene. Indeed, we were able to annotate only 
~30% of the detected CpGs (Table 19). However, the biological relevance of the genes 
that we were able to identify was confirmed by a literature research that showed how 
many of them were already involved in brain disorders or functions: Asic2 [372], Itih4 
[373], Mad1l1 [374], Mtm1 [375], Robo1 [376, 377], Disc1 [378-380], Hip1 [381].  
To gain some more knowledge about the overall biological function of all the CpGs 
detected by RRBS, we performed gene ontology analysis which indicated an enrichment 
in genes involved either in psychiatric disorders, glutamate neurotransmitter system or 
brain functions.  
For example, we detected Netrin 4 (NTN4), which is a gene involved in the formation of 
neurites that has been already implicated in the pathogenesis of TS in two genetic 
association studies [49, 325]. Another gene already associated with TS [27, 32] is 
Neurexin 1 (NRXN1), which encodes for a pre-synaptic cell-adhesion molecules involved 
in the growth of synapses and in the transmission of glutamate and GABA signals.  
An interesting gene is phosphodiesterase 10A (PDE10A), which belongs to a family 
involved in the regulation of cyclic nucleotide (cAMP) and that might influence 
locomotor movements as well as the expression of CREB [137, 382]. Another example is 
Reelin (RELN), which modulates neuronal microtubules as well as the migration of 




We also identified two genes (GRM4 and GRM8) belonging to a metabotropic glutamate 
receptor family and two genes (GRIK3 and GRIK4) involved in the modulation of 
glutamate, the major excitatory neurotransmitter in the central nervous system. In 
particular, GRM4 and GRM8 are implicated in the inhibition of the cyclic AMP cascade 
and they have been linked to epilepsy, depression, schizophrenia, depression, and alcohol 
abuse [385-388]. On the other hand, GRIK3 and GRIK4 function as ligand-activated ion 
channels and have been linked to depression and alcohol abuse [389, 390]. 
The involvement of glutamate was corroborated by a family of genes (CACGN4 and 
CACGN8) related to glutamate neurotransmission, by the regulation of AMPA receptor 
activity, already involved in schizophrenia [391]. One direct link to epigenetics is 
represented by DNMT3A, a gene that encodes for a DNA methyltransferase involved in 
the establishment of new methylation pattern. It is possible to speculate that abnormalities 
in the function of DNA methyltransferase might lead to prolonged changes in gene 
expression behind the manifestation of involuntary locomotor activity.  
Furthermore, we identified Serum/glucocorticoid regulated kinase 1 (SGK1), a 
serine/threonine kinase activated by the PI3K signal which is highly expressed in the 
neurons of several diseases such as PD, Huntington's disease and amyotrophic lateral 
sclerosis [392-395]. We also detected methylation changes in 3 CpGs nearby Cadherin 
13 (CDH13), which is involved in the negative regulation of axon growth and it may also 
protect endothelial cells from oxidative stress induced apoptosis it has been found hyper-
methylated in many types of cancer [393] and linked to five of the major neuropsychiatric 
disorders: autism, schizophrenia, bipolar disorder, depression and ADHD [396].  
Interestingly, glutamate is a frequent term in the gene enrichment analysis. It is quite 
normal to find glutamate in the group treated with Riluzole since it is a glutamatergic 
drug, but it is very surprising to find glutamate also in the group treated only with L-
DOPA. The result of our analysis provides further support to the hypothesis of glutamate 
in the development of TS already suggested by both genetic and neuroimaging studies 
[70]. 
A similar enrichment has been identified by previous studies on dynamic DNA 
methylation [244, 368, 369, 397]. In our case, it is very interesting to note that treatment 
with L-DOPA only resulted in a high enrichment of glutamate terms, thus supporting the 




We also checked the genes identified in the methylation studies with the mRNA 
expression data and we did not find a direct and significant correlation between gene 
expression and methylation levels. This is consistent with other studies showing that some 
brain areas show no correlation between DNA methylation and mRNA expression [398-
400]. In our case, the genes for which we had data were either not picked up or not 
significantly expressed in the mRNA data. 
The identification of a single CpG in the proximity of a gene is usually not sufficient to 
correlate DNA methylation changes with the manifestation of a certain phenotype 
(locomotor activity in our case). It is important to remember that we are looking only at 
each single CpG in the exact moment when the samples were collected, the same CpG is 
then annotated to a nearby gene and we assume that any eventual variation of methylation 
will result in gene expression changes. However, in most of the cases, these assumptions 
do not necessarily represent the actual biological situation even though they constitute an 
important indication of the methylation profile. It is the main reason that usually brings 
researchers to perform some independent validation to strengthen the results. We could 
not perform any validation experiments, but we are very confident that the CpGs 
identified in the study reflect real changes since we used an extremely stringent threshold. 
By adopting such stringent parameters, we opted for specificity over selectivity and 
decided to be able to detect only real changes even though it would result in the potential 
loss of many CpGs. The main reason of such stringent threshold is the complexity of the 
analysis and the need to identify changes due to 6-OHDA injection, L-DOPA 
administration, Riluzole treatment. Finally, it important to remember that the DNA 
methylation data might suffer from limitation by sample size since we were able to 
analyze only 3 rodents for each experimental group and more experiment, as well as 
independent single gene validation studies, are definitely needed to increase the 
knowledge on the effect of 6-OHDA, L-DOPA and Riluzole on DNA methylation 
changes. However, considering the stringent criteria used in the analysis, the findings so 
far discussed are strong and they might be used for further validation studies. 
To conclude, we were able to show that chronic drug treatment can induce DNA 
methylation changes. It might be one of the causes involved in the appearance and 
intensity of abnormal locomotor activity. These dynamic changes are not influenced by 




7. CONCLUSION  
 
7.1 Genetic studies of Tourette Syndrome 
 
In this project, we looked at genetic variation in 3’UTR of TS candidate genes with a 
putative connection to binding sites for miRNA. The Real-Time PCR did not find any 
positive results. The meta-analysis detected a positive association between rs3750486 (p 
= 0.021) located on LHX6 and rs7795011 (p = 0.029) located on IMMP2L with TS. 
Moreover, the TDT test also picked up an over-transmission of the A allele of rs1042201 
(p = 0.029, χ2 = 4.787) located on AADAC and TS patients. These finding confirm the 
literature evidence already proposing these genes as some of the many components in the 
TS pathology. The genetic association study also showed how lower sample size and 
population stratification hamper statistical power and it emphasized the need of a large 
collaborative effort in order to overcome those limitations.  
Worth to mention, to solve the genetic turmoil, more studies on different population are 
needed since it is likely that many of the genetic variations propelling the development 
of TS might differ based also on the geographic area, as observed in many studies. This 
population difference might also help to explain the lack of replicating findings between 
different studies. 
In addition, to prove the actual role of miRNAs in the abnormal regulation of those genes 
as consequence of genetic variation (e.g. SNPs) functional validation studies are 
warranted.  
 
7.2 Epigenetic studies of Tourette Syndrome 
 
In this project, we looked at methylation differences on a genome-wide levels to study 
and identify some CpGs that might be involved in the manifestation of tics. The EWAS 
analysis did not find any significant methylation changes even though it provided some 
interesting genes for follow-up studies. However, it would be optimal to increase the 
sample size (to have more statistical power) or to better define the phenotype of TS 
patients (to have more defined analyses). To conclude, we showed that epigenetic may be 




7.3 Abnormal Involuntary Movements (AIMs) animal model 
In this project, we looked at the effect of L-DOPA administration and Riluzole treatment 
on mRNA and DNA methylation in an animal model of AIMs. The behavioral data 
showed that Riluzole reduced the appearance of involuntary movements. The mRNA data 
demonstrated that Riluzole completely overturns the expression of genes involved in the 
regulation of apoptosis. The molecular landscape identified CREB1 (activation through 
phosphorylation) as the pivotal player in the appearance/reduction of AIMs. However, 
this molecular mechanism requires follow-up studies to be confirmed. It could be 
considered to test new/existing treatment for AIMs. 
On the other side, the DNA methylation studies did not provide converging results as the 
transcriptome analysis. However, we gained knowledge on the changes in DNA 
methylation levels in animal model of AIMs. Indeed, the DMSs analysis revealed that 
lesioned and contralateral striatum have almost identical methylation profiles. In addition, 
we clearly observed that various treatments (L-DOPA administration or Riluzole 
treatment) had no differential effect on the methylation profile (lesioned or contralateral). 
Furthermore, the gene ontology showed the likely contribution of glutamate in the 
appearance of locomotor activity and it also provided different genes for follow-up 













8. SUMMARY  
Tourette Syndrome is a neurodevelopmental disorder characterized by the appearance of 
involuntary locomotor and vocal activity (tic). The etiology of TS is still far from being 
understood. The European union decided to approach this disorder with a team made of 
12 PhD students spread in universities and pharma companies (TS-EUROTRAIN). 
The PhD dissertation described above originates from the extensive exchange of 
individual skills, scientific knowledge and biological samples.  
In this PhD project we screened genetic variations in the 3’UTR of TS candidate genes. 
The use of meta-analysis and TDT test, as required by the dataset at our disposal, detected 
three TS positive association. In details, we picked up rs3750486 located in LHX6, 
rs7795011 located in IMMP2L, and rs1042201 located in AADAC. These genetic findings 
confirm the literature evidences linking the genes with TS pathology.  
We also looked, for the first time, at genome wide methylation differences in blood 
samples of patients manifesting tic phenotype. The analysis did not find any significant 
CpG site even though it provided some interesting genes for follow-up studies. For 
examples: GABBR1 gene linked to the major inhibitory neurotransmitter (GABA) in the 
central nervous and the MOZ/MORF complex. 
In addition, we investigated effect of L-DOPA administration and Riluzole treatment on 
mRNA and DNA methylation profile of Abnormal Involuntary Movements (AIMs) 
rodent model. The behavioral data clearly showed that Riluzole is able to stop the 
appearance of locomotor activity. The molecular landscape built using mRNA data 
identified CREB1 (its activation through phosphorylation) as a pivotal player in the 
appearance/reduction of AIMs.  
On the other side, the DNA methylation studies did not provide the same converging 
results as the transcriptome analysis. However, we gained knowledge on the changes in 
DNA methylation levels in animal model of AIMs. Indeed, the DMSs analysis revealed 
that lesioned and contralateral striatum have almost identical methylation profiles. In 
addition, we clearly observed that various treatments (L-DOPA administration or 
Riluzole treatment) had no differential effect on the methylation profile (lesioned or 
contralateral). Furthermore, the gene ontology showed the likely contribution of 
glutamate in the appearance of locomotor activity and it also provided different genes for 




9. ÖSSZEFOGLALÁS  
 
A Tourette-szindróma (TS) akaratlan mozgásszervi és hangbeli aktivitással (ún. tic) járó 
idegfejlődési rendellenesség. A TS etiológiája még nem teljesen feltárt. Az Európai Unió 
megbízásából egy TS-EUROTRAIN elnevezésű, több egyetemről és gyógyszercégtől 
jövő 12 PhD hallgatóból álló csoport foglalkozik a rendellenesség megértésével. A fent 
tárgyalt PhD disszertáció az egyéni képességek, tudományos tudás és biológiai minták 
széleskörű, kölcsönös cseréjéből származik. Jelen PhD projekt során TS-kandidáns gének 
3’ UTR részében található genetikai variációk vizsgálatával foglalkoztunk. A 
rendelkezésre álló adathalmazon végzett meta-analízis és TDT-teszt 3 TS-pozitív 
asszociációt mutatott ki: az LHX6-ban elhelyezkedő rs3750486, az IMMP2L-ben 
elhelyezkedő rs7795011és az AADAC-ben elhelyezkedő rs1042201. Ezek a genetikai 
találatok megerősítik az irodalmi adatokat, melyek szerint ezek a gének kapcsolatba 
hozhatók a TD patológiájával. Elsőként mi vizsgáltuk meg a genomszintű metilációs 
különbségeket tic-fenotípussal rendelkező betegek vérmintáiban. Az analízis nem tárt fel 
CpG-helyekhez kapcsolódó szignifikáns különbségeket, de a találatok között van néhány 
érdekes gén, melyeket érdemes tovább követni, például a GABBR1 gén, mely a központi 
idegrendszer fő gátló neurotranszmitteréhez (GABA) kapcsolható és a MOZ/MORF 
komplex. Továbbá, megvizsgáltuk az L-Dopa- és riluzol-kezelés hatását mRNS és DNS-
metilációs szinten AIM („abnormális akaratlan mozgások”) rágcsáló modellben. A 
viselkedési tesztek adatai egyértelműen megmutatták, hogy riluzol képes megállítani a 
mozgásszervi aktivitás megjelenését. Az mRNS adatokból megalkotott molekuláris 
tájkép a CREB1-et azonosította, mely – foszforilációval történő aktivációja által – 
kulcsszerepet játszik az AIM megjelenésében és eltűnésében. Másrészről, a DNS-
metilációs vizsgálatok nem mutattak olyan összefüggő eredményeket, mint a 
transzkripciós analízis. Azonban tudást szereztünk a DNS-metilációs szintek változásáról 
AIM egérmodellben. A DMS-analízis feltárta, hogy a léziós és az ellentétes oldali 
striatum metilációs profilja közel azonos. Továbbá, egyértelműen kimutattuk, hogy a 
különböző kezeléseknek (L-Dopa vagy riluzol) nincs megkülönböztető hatása a 
metilációs profilra nézve (léziós és ellenoldali). Végül, a génontológia a glutamátot egy 
lehetséges közreműködőként azonosította a mozgásszervi aktivitás megjelenésében, és 
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